{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2025-09-19", "results": { "skip": 0, "limit": 1, "total": 1 } }, "results": [ { "codes": [ { "uuid": "fe5e387e-b97b-4c1c-892b-9dc7db5c3544", "code": "B6L4N5Z4GH", "type": "PRIMARY", "code_system": "FDA UNII" } ], "relationships": [ { "uuid": "94278621-f422-4c97-9065-098e3c3ec295", "amount": { "uuid": "80f80cd8-82a0-4f89-9a45-33d3d8984381" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "179cad9d-4c69-44b3-9b9a-e3197c7164e9" ], "related_substance": { "uuid": "8b880e2d-399c-49f6-af9d-86b76f4455f0", "refuuid": "6cf5c858-21a4-46e8-88d9-40624fac1d51", "name": "R-AD5-S (RECOMBINANT ADENOVIRUS TYPE 5 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)", "unii": "TJ5C56A5DW", "linking_id": "TJ5C56A5DW", "ref_pname": "R-AD5-S (RECOMBINANT ADENOVIRUS TYPE 5 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)" } }, { "uuid": "df296698-1c66-48e5-9696-65f34de9d292", "amount": { "uuid": "cdbe63b6-9ecd-4c6e-96a1-5b34a7075573" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "379c8b9f-c192-4e8d-b201-801c863ac779" ], "related_substance": { "uuid": "6d22b4ce-4dba-47ae-af40-036d4e4b9a21", "refuuid": "5338e2e1-20e5-4ba3-9039-dc029f9af9cc", "name": "R-AD26-S (RECOMBINANT ADENOVIRUS TYPE 26 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)", "unii": "C3JH443FGL", "linking_id": "C3JH443FGL", "ref_pname": "R-AD26-S (RECOMBINANT ADENOVIRUS TYPE 26 CARRYING THE GENE FOR SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-COV-2) SPIKE GLYCOPROTEIN)" } }, { "uuid": "18122da6-a318-4324-a712-369ed97852dc", "amount": { "uuid": "fa22fc30-14c7-415d-9dd0-56c40014c196" }, "comments": "A guanine derivative approved for treating HCV and respiratory syncytial virus (RSV) that has been evaluated in patients with SARS and MERS, but its side effects such as anaemia may be severe at high doses.", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "5be80393-b5bb-49c5-b751-ca1d38a471d7" ], "related_substance": { "uuid": "e73532b2-23c4-4ad0-bb68-e710773b1e4d", "refuuid": "63e3a2fd-1881-44bb-8d8d-469f6400ec4f", "name": "RIBAVIRIN", "unii": "49717AWG6K", "linking_id": "49717AWG6K", "ref_pname": "RIBAVIRIN", "substance_class": "reference" } }, { "uuid": "dd30c7f6-7c48-491c-99a1-537d1b8cde74", "amount": { "uuid": "7fc614d6-290d-4823-872c-75e16f312460" }, "comments": "Has shown antiviral activities in preclinical studies against many RNA viruses, including SARS and MERS. ", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "5be80393-b5bb-49c5-b751-ca1d38a471d7" ], "related_substance": { "uuid": "f31b2f85-1683-4dd8-aeea-8ed455059991", "refuuid": "e6b061eb-b555-42ae-88c9-1cd8cd979d7d", "name": "GALIDESIVIR", "unii": "OLF97F86A7", "linking_id": "OLF97F86A7", "ref_pname": "GALIDESIVIR", "substance_class": "reference" } }, { "uuid": "249e2b7c-9456-4d8c-b9db-3d60b8bdec5e", "amount": { "uuid": "3f0acb3e-f87d-4067-8fe7-18163ff34e29", "average": 770, "units": "NANOMOLAR" }, "comments": "In Vero E6 cells inhibits. Targets the RNA-dependent RNA polymerase and block viral RNA synthesis in a broad spectrum of RNA viruses, including human coronaviruses. A US patient with 2019-nCoV recovered after receiving intravenous remdesivir in January", "qualification": "EC50", "type": "INHIBITOR->TARGET ORGANISM", "interaction_type": "BIOASSAY (CELLULAR)", "references": [ "5be80393-b5bb-49c5-b751-ca1d38a471d7" ], "related_substance": { "uuid": "9f401d4a-74b1-4b31-ba9b-2f3e2a25e4c8", "refuuid": "c09f4a11-ce2e-437a-95da-e2d3f82308ad", "name": "REMDESIVIR", "unii": "3QKI37EEHE", "linking_id": "3QKI37EEHE", "ref_pname": "REMDESIVIR", "substance_class": "reference" } }, { "uuid": "db2c84c7-31f2-43e5-82cd-538deb6a3e08", "amount": { "uuid": "aa7cca77-03cf-4300-9737-fc3df11e1b5c" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "65b57406-e7aa-4b38-82ee-d06246ebc3e3" ], "related_substance": { "uuid": "4938aae5-fa40-4064-b199-5be29649e680", "refuuid": "3256f533-f53d-49b7-82f2-c8ba5f85c7a8", "name": "CASIRIVIMAB", "unii": "J0FI6WE1QN", "linking_id": "J0FI6WE1QN", "ref_pname": "CASIRIVIMAB" } }, { "uuid": "7dbacdb2-99d2-4609-b9a8-14ac391fa95c", "amount": { "uuid": "22639abd-69f9-4b65-974f-201993040292" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "185b8f94-2f0c-48ca-96f1-c7048967a2a8" ], "related_substance": { "uuid": "ec73c04e-7a20-4107-8a00-951a6b117e20", "refuuid": "231f804d-778a-4e71-820a-a13a1af72319", "name": "ETESEVIMAB", "unii": "N7Q9NLF11I", "linking_id": "N7Q9NLF11I", "ref_pname": "ETESEVIMAB" } }, { "uuid": "c6aebdf0-c56a-4272-9f2c-3a8ca2016903", "amount": { "uuid": "fbde3432-264e-47de-8fae-26bacf93312e" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "63288014-e64d-434d-9565-ed5083bb231c" ], "related_substance": { "uuid": "0014df2a-c11d-4d2a-8d1c-18c5e1bdf328", "refuuid": "f4811aba-990e-354a-87d7-f172b407046f", "name": "SAB-185", "unii": "GZH7FFK82R", "linking_id": "GZH7FFK82R", "ref_pname": "SAB-185" } }, { "uuid": "ca574023-06e0-4c34-a11f-25788e5bdeb0", "amount": { "uuid": "e6e18f63-eb5e-4c62-aac0-d63a4f7f6625" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "244f3afd-5635-4bbf-a544-f68c256f72b8" ], "related_substance": { "uuid": "1a3a6bf9-4244-48c2-a7a3-f5237509db94", "refuuid": "5a38549e-5363-9fb3-0e9d-531cee08913c", "name": "GS-441524", "unii": "1BQK176DT6", "linking_id": "1BQK176DT6", "ref_pname": "GS-441524" } }, { "uuid": "6e2c1c56-babb-456d-9d53-bf9beb06d024", "amount": { "uuid": "cbe897ed-1486-49bd-b85f-9ed904e3389a" }, "type": "INHIBITOR->TARGET", "references": [ "a9672f40-bcfe-4eab-bfbe-08b08f82f50d", "233f7d0b-36ee-45cd-be63-48012d83baac" ], "related_substance": { "uuid": "474e0d5b-2863-46db-a303-d16ffbd16162", "refuuid": "9f946c74-87b4-4dab-a346-34e677a76671", "name": "COVID-19 CONVALESCENT PLASMA", "unii": "YM6LN8TU2V", "linking_id": "YM6LN8TU2V", "ref_pname": "COVID-19 CONVALESCENT PLASMA" } }, { "uuid": "398fcf95-661e-4f77-b7e3-b9be0dcd3f1f", "amount": { "uuid": "b3163c4a-de0d-4fd5-88ea-fdc40aa5e725" }, "comments": "The antibody binds selectively to the spike protein of SARS-CoV-2.", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "106c1271-4d9e-41e3-97b7-dd4e3712ac5f" ], "related_substance": { "uuid": "9f3fc94c-3c5d-49cb-b86f-2852e3c02c25", "refuuid": "3a279ffb-5bf3-4df2-879b-a7a214349685", "name": "BAMLANIVIMAB", "unii": "45I6OFJ8QH", "linking_id": "45I6OFJ8QH", "ref_pname": "BAMLANIVIMAB" } }, { "uuid": "1589408b-4baf-4afe-b6f2-6716bd2cc108", "amount": { "uuid": "1ebe7b52-c20f-4589-880b-311d2029cbb0" }, "comments": "DRUG APPROVED IN CHINA FOR COVID-19. Prodrug that InhibitS the RNA-dependent RNA polymerase after activation to triphosphate.", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "28e7c16c-fd65-4ed0-8924-21aede66e888" ], "related_substance": { "uuid": "80e5903c-f79b-46a7-a891-17a57da6aefd", "refuuid": "53c790e8-19cf-4a7c-b0ee-05e2c0a15c32", "name": "FAVIPIRAVIR", "unii": "EW5GL2X7E0", "linking_id": "EW5GL2X7E0", "ref_pname": "FAVIPIRAVIR" } }, { "uuid": "8f91d5d4-d917-4e8f-b1c7-5f3cd9e1b1a6", "amount": { "uuid": "7f1948c8-b63c-4493-8cc9-3712295cb9d9" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "fa877105-f095-46b5-9321-b911b0c757f1" ], "related_substance": { "uuid": "b38d6150-439b-4622-a5d6-ed244e611684", "refuuid": "9ec09c79-71ca-41f2-ba5f-c07565064c20", "name": "TIXAGEVIMAB", "unii": "F0LZ415Z3B", "linking_id": "F0LZ415Z3B", "ref_pname": "TIXAGEVIMAB" } }, { "uuid": "7abf1dbb-0184-4fc5-9bf3-37be527a3181", "amount": { "uuid": "c24cda0e-fbdf-48b7-bc18-d6bf32f1eac5" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "255168da-653e-4af0-baf8-a2d53b3c5116" ], "related_substance": { "uuid": "27c4dea5-d99e-47c7-a306-123b7a6a4767", "refuuid": "8cc5abde-8ba9-48e2-8cf9-af85e264c3ac", "name": "SPIKE GLYCOPROTEIN (SARS-COV-2) (336-350)", "unii": "FN55K29HD1", "linking_id": "FN55K29HD1", "ref_pname": "SPIKE GLYCOPROTEIN (SARS-COV-2) (336-350)" } }, { "uuid": "334012e1-5327-4635-a931-113ad8d0bfb7", "amount": { "uuid": "bbc30379-f624-4bb0-b5d6-0591ca425d92" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "bfc52397-de39-4e17-97a5-cd15fb05ad9e" ], "related_substance": { "uuid": "7ab296f6-8ca9-483e-abf7-db25c96282b3", "refuuid": "4860be69-c53c-47eb-8d1e-09367d2f6b7b", "name": "SPIKE GLYCOPROTEIN (SARS-COV-2) (339-347)", "unii": "775U4AS43Q", "linking_id": "775U4AS43Q", "ref_pname": "SPIKE GLYCOPROTEIN (SARS-COV-2) (339-347)" } }, { "uuid": "002f138d-1ff4-4f0a-abbf-5e88380413d5", "amount": { "uuid": "291d9deb-d169-4422-b9fa-44f2ac55958d" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "9fd55f89-dbd1-48dc-b3e3-d4426105c6fe" ], "related_substance": { "uuid": "0c377b64-07bb-4fab-b224-779e9fd6a93f", "refuuid": "a256fe4c-c71e-447a-ac82-ab853a6c7bec", "name": "CILGAVIMAB", "unii": "1KUR4BN70F", "linking_id": "1KUR4BN70F", "ref_pname": "CILGAVIMAB" } }, { "uuid": "c122e5a1-6ed3-4747-a6ef-26a29ca2aa6b", "amount": { "uuid": "bb4fbdaa-f4b0-4c46-8061-b35dd9ab8d94" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "e0c0e5df-af82-4af6-8493-f924b3ff918a", "refuuid": "b0fdb524-5853-4127-a4eb-95bba5d60861", "name": "AMUBARVIMAB", "unii": "2AD5KH3SE4", "linking_id": "2AD5KH3SE4", "ref_pname": "AMUBARVIMAB" } }, { "uuid": "c63c5af9-afca-449a-b71c-0d9ed23c4920", "amount": { "uuid": "7aee1058-fb71-44a2-8bcf-cd30bb8bda26" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "4a601f59-ae3b-493b-837d-aab9cbbdb106", "refuuid": "cd0990ed-a00c-470e-ae07-cf105f90f5f9", "name": "ROMLUSEVIMAB", "unii": "SM01RRU9KK", "linking_id": "SM01RRU9KK", "ref_pname": "ROMLUSEVIMAB" } }, { "uuid": "36bafec8-037f-4f05-ba48-ec2804003aa1", "amount": { "uuid": "4bec965c-0f25-449f-8f35-ac7cdeb94e6e" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "de23010a-ce00-4910-84ec-9395c0fcb53b" ], "related_substance": { "uuid": "f32dbd5a-adbc-4a83-a0e1-56c473f0acb2", "refuuid": "a5690b64-7532-45f6-9755-a65ed6f27eb6", "name": "SARS-COV-2 CN2 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN", "unii": "M1QXB372B8", "linking_id": "M1QXB372B8", "ref_pname": "SARS-COV-2 CN2 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN" } }, { "uuid": "ebcda350-6d3a-4350-bd20-f58252b77d4a", "amount": { "uuid": "a830a1da-aa54-4cec-b284-d85b48f6e4e6" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "ee652234-3ac8-4977-acab-4b1870323311" ], "related_substance": { "uuid": "aae5b007-e628-4fa6-866a-2b38e7c152ae", "refuuid": "da3480e9-3a1e-4976-8daa-0b912b2e8fbe", "name": "NVX-COV2373", "unii": "UK9AK2IN1P", "linking_id": "UK9AK2IN1P", "ref_pname": "NVX-COV2373" } }, { "uuid": "2d52f139-76a8-44a6-b155-4eed062d1557", "amount": { "uuid": "23c97635-dc8c-4561-85db-aa74cc7fcc0e" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "b1f9afc9-b08f-48ad-bf05-ba377305cb74", "refuuid": "4c0b6369-fb4b-418e-8afc-58be6e442393", "name": "ENUZOVIMAB", "unii": "D474BW0A5E", "linking_id": "D474BW0A5E", "ref_pname": "ENUZOVIMAB" } }, { "uuid": "eec016d9-4e44-4e9e-91af-9c0f6a263fc4", "amount": { "uuid": "ed9d5339-d2b1-4e8a-8b15-cc2f1bc494e3" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "534c4c3b-590f-47e3-8091-a6a8966b5b08" ], "related_substance": { "uuid": "c55bef99-7ed5-4e27-9664-cad50c4af8aa", "refuuid": "17f85581-e938-4931-8b0f-30c4aa0ab358", "name": "GANULAMERAN", "unii": "I74C16KK3J", "linking_id": "I74C16KK3J", "ref_pname": "GANULAMERAN" } }, { "uuid": "59652805-31fe-4628-9fbb-ac86a6a7680d", "amount": { "uuid": "ee99326a-9558-4cf8-bc4e-946e8bd24ad2" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "2bc33d89-8dc6-429a-af1e-08e8b59405c1" ], "related_substance": { "uuid": "830e1311-306a-4f4d-ba63-7d3b5ef52a95", "refuuid": "74f53363-2a6d-4673-ba53-2c6bfe324bb8", "name": "PIDACMERAN", "unii": "6FH8H9CL41", "linking_id": "6FH8H9CL41", "ref_pname": "PIDACMERAN" } }, { "uuid": "ad841189-a3e1-4bc7-b830-98c64aa8ec14", "amount": { "uuid": "8796fae6-ed60-4788-a041-d125f4425e13" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "44405223-bea9-48ce-8acc-8cda6ef98247" ], "related_substance": { "uuid": "be68a56f-a6e7-423b-8c3b-12598c8f407b", "refuuid": "5b593c04-8131-4564-a1c9-8565004f4eb5", "name": "ZORECIMERAN", "unii": "5TP24STD1S", "linking_id": "5TP24STD1S", "ref_pname": "ZORECIMERAN" } }, { "uuid": "3e3a9b2f-7cc2-4b95-bd73-5b4d1cbcff10", "amount": { "uuid": "65a25bed-e584-46d4-86de-ff501541bc5b" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "bb15498a-d3cb-427c-b5a0-5b2617ffb941" ], "related_substance": { "uuid": "227414d3-d326-4591-b62c-f310d6938b7c", "refuuid": "2c9b6edd-a1a8-401d-a727-1d51f69af1c8", "name": "47D11", "unii": "20YWF2NH7O", "linking_id": "20YWF2NH7O", "ref_pname": "47D11" } }, { "uuid": "fd1e3f0e-d8a7-43d8-89a3-76b304f45d28", "amount": { "uuid": "5876a71d-4695-4ec4-9224-a913937d39b3" }, "type": "INHIBITOR->TARGET ORGANISM", "interaction_type": "IN-VITRO", "references": [ "502c9214-4470-4628-8213-26093592ba8e" ], "related_substance": { "uuid": "f3451dcd-8e35-42aa-b5a5-22a41d943fd3", "refuuid": "aa6536be-3960-4fa0-847b-17c2d373fb22", "name": "PLUTAVIMAB", "unii": "12U14K0SR5", "linking_id": "12U14K0SR5", "ref_pname": "PLUTAVIMAB" } }, { "uuid": "488f6622-ae45-4f27-9427-8f3f6807499a", "amount": { "uuid": "c8698f58-4a50-4fdc-b3df-e29705e1d481", "average": 70, "high": 90, "low": 62, "units": "%" }, "comments": "One dosing regimen (n=2,741) showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart, and another dosing regimen (n=8,895) showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens (n=11,636) resulted in an average efficacy of 70%. no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. There were a total of 131 COVID-19 cases in the interim analysis", "qualification": "EFFICACY", "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "748a8e4f-6f36-42fb-a2b3-9873e3b08063" ], "related_substance": { "uuid": "45ce3496-dc2e-4384-bce4-b51de5fadcb3", "refuuid": "37a1461f-a7a3-4550-aaab-d04fc8ae33b4", "name": "AZD-1222", "unii": "B5S3K2V0G8", "linking_id": "B5S3K2V0G8", "ref_pname": "AZD-1222" } }, { "uuid": "bd5df81b-57c1-429f-8a76-04d71bf60b00", "amount": { "uuid": "3420c391-85c8-4177-a1db-9f2e7d8a7420" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "related_substance": { "uuid": "04f265d4-ac5b-4546-975e-7013fd612423", "refuuid": "8d1ff747-79d5-43af-b822-9d5de7446932", "name": "AD26.COV2.S", "unii": "JT2NS6183B", "linking_id": "JT2NS6183B", "ref_pname": "AD26.COV2.S" } }, { "uuid": "9264f705-e7ab-4074-855a-0f619c1b9d2d", "amount": { "uuid": "48b61f31-8244-4401-bbe2-1bb8fca844d7" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "092b6adc-02c2-458b-8767-ed6b8ba75e95", "refuuid": "525ed344-27b9-4f1c-974c-d43b4c38126e", "name": "SOTROVIMAB", "unii": "1MTK0BPN8V", "linking_id": "1MTK0BPN8V", "ref_pname": "SOTROVIMAB" } }, { "uuid": "c0ee1542-0e69-4de7-9d31-9d836b6dcfc2", "amount": { "uuid": "af638bd7-c5b4-4c34-af63-b6e9d6b13b81" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "c1c39f11-4237-4384-a4d5-15ab545d1b3b", "refuuid": "4d0c40c7-974f-47c2-a5c5-8c9590690ecd", "name": "REGDANVIMAB", "unii": "I0BGE6P6I6", "linking_id": "I0BGE6P6I6", "ref_pname": "REGDANVIMAB" } }, { "uuid": "6a522bfd-64e8-4a63-8031-396ededa4dc6", "amount": { "uuid": "27471089-c0ee-431b-b028-4263c3cd547c" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "545483c7-e967-47df-b041-70c0d753a504" ], "related_substance": { "uuid": "22681cdd-5c9d-402c-96e2-cd62652ceb77", "refuuid": "3013dcf4-cad6-6b55-a166-bbbe8f2513f4", "name": "SARS-COV-2 WIV04 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN", "unii": "GQ10EO148M", "linking_id": "GQ10EO148M", "ref_pname": "SARS-COV-2 WIV04 STRAIN .BETA.-PROPIOLACTONE INACTIVATED VACCINE ANTIGEN" } }, { "uuid": "f1001523-d8b5-4dea-bd75-395dffb07072", "amount": { "uuid": "116f5c0e-ddff-4347-b9ba-5f752cc85ce7" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "ba8c3a23-62c9-471d-99e6-bb8274fae69a" ], "related_substance": { "uuid": "817a7df4-8e32-4c13-83bb-64628e349e52", "refuuid": "a566142d-b559-4344-b477-99e9fe653108", "name": "MOLNUPIRAVIR", "unii": "YA84KI1VEW", "linking_id": "YA84KI1VEW", "ref_pname": "MOLNUPIRAVIR" } }, { "uuid": "64161835-f272-408b-b511-4961680a1c5e", "amount": { "uuid": "6fbdaf44-cb0c-47e9-b5d7-2eaedbcf77b3" }, "comments": "In vitro study showed that Camostat reduces significantly the infection of Calu-3 lung cells by SARS-CoV-2, the virus responsible for COVID-19.", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "7c876b3f-408e-4317-96f9-5c6145a2b25c", "256da0c0-0682-40cf-8e8c-1bf60acb1fb3" ], "related_substance": { "uuid": "3d244687-8e43-4017-82ff-acdacd862f70", "refuuid": "16d9bafe-cf0d-4ac4-b7ed-e10747ef2d62", "name": "CAMOSTAT", "unii": "0FD207WKDU", "linking_id": "0FD207WKDU", "ref_pname": "CAMOSTAT", "substance_class": "reference" } }, { "uuid": "b5c87b75-6ac7-44c1-b16b-2c89527418fc", "amount": { "uuid": "68bc4987-8ef0-4cc0-b697-c88255630d2f", "average": 6.14, "units": "MICROMOLAR", "non_numeric_value": "at 24 hours" }, "comments": "after 24 hours incubation; works in cell culture may not work in-vivo", "qualification": "EC50", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "f2f58432-563b-411e-8e22-226f7de051c8" ], "related_substance": { "uuid": "77cad0e1-cf29-4022-ad30-48583c445baa", "refuuid": "c745a4f9-bf57-489e-85dd-bafb3a8e7362", "name": "HYDROXYCHLOROQUINE", "unii": "4QWG6N8QKH", "linking_id": "4QWG6N8QKH", "ref_pname": "HYDROXYCHLOROQUINE", "substance_class": "reference" } }, { "uuid": "f0c8c78a-ec6b-48fc-9c86-554211a19a45", "amount": { "uuid": "3bdaab77-c91b-4584-953b-6c34997aba7b", "average": 1130, "units": "NANOMOLAR" }, "comments": "In Vero E6 cells", "qualification": "EC50", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "4b0010b5-bf69-4ef7-9352-902d3da9c441" ], "related_substance": { "uuid": "ebd8678d-093f-432d-97af-9c9b167b677e", "refuuid": "894c3067-06cf-47c2-ba1e-439f3330093e", "name": "CHLOROQUINE", "unii": "886U3H6UFF", "linking_id": "886U3H6UFF", "ref_pname": "CHLOROQUINE", "substance_class": "reference" } }, { "uuid": "5cdc2913-9e5c-4b50-a666-534702f4a64e", "amount": { "uuid": "7a348711-d2b3-4c74-895f-87c2b39fc1ff", "average": 2120, "units": "NANOMOLAR" }, "comments": "In Vero E6 cells", "qualification": "EC50", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "4b0010b5-bf69-4ef7-9352-902d3da9c441" ], "related_substance": { "uuid": "d0321e09-c76d-4779-8050-034de1b233eb", "refuuid": "d376d3e0-be69-4e7c-9ebc-51f004bfbbc4", "name": "NITAZOXANIDE", "unii": "SOA12P041N", "linking_id": "SOA12P041N", "ref_pname": "NITAZOXANIDE", "substance_class": "reference" } }, { "uuid": "ae350b6d-627c-4314-9b52-0249e775aa40", "amount": { "uuid": "256092e4-44b8-4263-ab01-d9e9b2d38544" }, "type": "PART/FRACTION->PARENT ORGANISM", "references": [ "c2046f69-25bf-42a5-9fc3-685188e48e28", "74c1580a-87c3-4629-8083-2b37250ec1af", "6a14f32b-ae14-4c2a-a7be-5443030c88aa" ], "related_substance": { "uuid": "3082733c-ae3a-4cb2-bf11-419bf4943661", "refuuid": "f72b8913-d64d-4194-b069-572520cc09f8", "name": "ORF1AB POLYPROTEIN (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2)", "unii": "E749PN51FV", "linking_id": "E749PN51FV", "ref_pname": "ORF1AB POLYPROTEIN (SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2)" } }, { "uuid": "1d45a622-2700-43a8-975d-5be5f9e1e6fa", "amount": { "uuid": "67d2770a-7254-460f-bc8a-d4fdc596ed4b" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "dea419ef-ae37-4dd6-89c2-b38b9d843224", "refuuid": "66ccc755-06c2-43e2-ab6f-5188473afbac", "name": "UMIFENOVIR", "unii": "93M09WW4RU", "linking_id": "93M09WW4RU", "ref_pname": "UMIFENOVIR", "substance_class": "reference" } }, { "uuid": "d524da1b-0c2a-40f1-bb17-022a543dd572", "amount": { "uuid": "350f21f6-5304-4a81-b841-ddd6f0b25b5c" }, "type": "VACCINE ANTIGEN->TARGET", "references": [ "c2fcbd6f-0cbe-4233-a396-cf39f2896dc1" ], "related_substance": { "uuid": "0c3f2206-a61c-45e2-9600-49ebaa6021e6", "refuuid": "f413415a-df92-4fe9-8729-d6a1732082af", "name": "Zapomeran", "unii": "J9E7RSF8K3", "linking_id": "J9E7RSF8K3", "ref_pname": "Zapomeran", "substance_class": "reference" } }, { "uuid": "5c2180b3-0805-436e-b2eb-4b26c1bc000c", "amount": { "uuid": "231eed51-6d32-46d0-964b-b8a59a11b1ed" }, "type": "VACCINE ANTIGEN->TARGET", "related_substance": { "uuid": "4072a5ec-2f1e-41c6-8828-c5bc00babb32", "refuuid": "981744e9-0ca2-400b-a20c-602353f9d5fb", "name": "CVXGA1", "unii": "JVG3CC2YJ4", "linking_id": "JVG3CC2YJ4", "ref_pname": "CVXGA1" } }, { "uuid": "41b4d605-973e-4df0-8a65-ec89708118d7", "amount": { "uuid": "2a629797-b707-42a4-86b7-ca2808ef5819" }, "type": "VACCINE ANTIGEN->TARGET", "references": [ "ea0681c2-da4c-45d0-bb18-24c67b6db3f6" ], "related_substance": { "uuid": "6b1ea687-712c-4eaa-9a3d-980a0501db4e", "refuuid": "6e2b29e6-3fd5-4d7d-be6a-fc846b6e677c", "name": "Ufrenmeran", "unii": "AP7FFK83RM", "linking_id": "AP7FFK83RM", "ref_pname": "Ufrenmeran", "substance_class": "reference" } }, { "uuid": "5905c0e6-b1c9-4b7a-ac0e-1f9341307dd2", "amount": { "uuid": "207bc76f-4ae7-4714-ae11-af4eba5e6006" }, "type": "INHIBITOR->TARGET", "references": [ "5f91cef5-0781-44a3-9497-95b81a257129" ], "related_substance": { "uuid": "fac25870-49e5-4c4f-b0ae-0bc0ce62de01", "refuuid": "3c77a4e5-4e93-4733-89c7-4c8030f2415b", "name": "HUMAN ANTI-SARS-COV-2 IMMUNOGLOBULIN", "unii": "VF62JD6WN3", "linking_id": "VF62JD6WN3", "ref_pname": "HUMAN ANTI-SARS-COV-2 IMMUNOGLOBULIN" } }, { "uuid": "f9261345-7feb-475b-91bc-62f285a13d1b", "amount": { "uuid": "508ad08a-dac2-4a37-accc-995bb44add3e" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "5da3a666-603a-4b97-9787-c24142df810a" ], "related_substance": { "uuid": "f598cc85-19ea-4d21-8dc1-bf39f9b93c0f", "refuuid": "2d34e720-e21d-4b69-9e4f-679cc49b9ad6", "name": "GS-621763", "unii": "83BU3492RP", "linking_id": "83BU3492RP", "ref_pname": "GS-621763", "substance_class": "reference" } }, { "uuid": "9b51bb58-6608-43c2-a33c-0d482841e30d", "amount": { "uuid": "c723b2c0-c938-4847-bf44-d701d1bcbf0a" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "441af35e-932e-42e3-8cc9-c5b0e1432c82" ], "related_substance": { "uuid": "2243f16e-dc71-430f-b2bd-8cf29671d2b2", "refuuid": "2f705926-1abf-4f8f-8f45-a56715dc1f42", "name": "DARAPLADIB", "unii": "UI1U1MYH09", "linking_id": "UI1U1MYH09", "ref_pname": "DARAPLADIB", "substance_class": "reference" } }, { "uuid": "d343862f-121a-4de7-9134-4a87830beca9", "amount": { "uuid": "bf14721a-6751-4e94-93dc-e527569de4f8" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "c753ef2e-babc-4663-81cc-52992f6b7451", "refuuid": "cc56963f-4e72-4d95-bb74-d9eb0b82a8c8", "name": "LUFOTRELVIR", "unii": "XJ51YOB1SC", "linking_id": "XJ51YOB1SC", "ref_pname": "LUFOTRELVIR", "substance_class": "reference" } }, { "uuid": "7704c39e-68bb-4315-b99c-f11d3a4cef7d", "amount": { "uuid": "cb1501af-58f1-4148-8f6b-1235cc473b14" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "49f99fa0-85b9-4e77-8715-a1bbb379654e" ], "related_substance": { "uuid": "93d90b70-d166-459c-bb3a-394d5f6d6700", "refuuid": "ffa00d5b-c123-4760-9240-d326bfdd1839", "name": "Sipavibart", "unii": "977D2P9YYW", "linking_id": "977D2P9YYW", "ref_pname": "Sipavibart", "substance_class": "reference" } }, { "uuid": "8077bfe4-5637-4b29-89a9-81b57068faa0", "amount": { "uuid": "855ec514-2744-4d7d-914d-7fcd1b73ca16" }, "type": "INHIBITOR->TARGET", "references": [ "6c8b49ac-0c22-435e-b3cd-afd4a7deef65" ], "related_substance": { "uuid": "0b027ee2-016b-44e0-892e-5d6d6ca496c3", "refuuid": "e7eed733-892e-4ff0-af6e-9c11f4875dc2", "name": "SIMPINICLINE", "unii": "09936A4QSN", "linking_id": "09936A4QSN", "ref_pname": "SIMPINICLINE", "substance_class": "reference" } }, { "uuid": "a42a48e9-fe51-406c-8f1e-eec3b65d086c", "amount": { "uuid": "1e053f31-0809-4670-b40e-49c789887358" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "8462f898-6d48-4986-97d6-76e9add6df6e" ], "related_substance": { "uuid": "fed40805-33be-4922-a3de-2a788b351c31", "refuuid": "a821ef2f-61a4-4987-b783-eb10ccfe05e4", "name": "Simaravibart", "unii": "5C4T4W973X", "linking_id": "5C4T4W973X", "ref_pname": "Simaravibart", "substance_class": "reference" } }, { "uuid": "33afcfee-f4b7-47a8-840c-0fbba62592ff", "amount": { "uuid": "66b15f6c-df9c-4846-af28-6a176ddc375e" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "0691cb96-c693-489a-a43e-40d2e5cd915e" ], "related_substance": { "uuid": "a9388060-b3f6-43f6-bcb4-955ad8516252", "refuuid": "4268be35-df3b-44f7-b216-4d866dc9782b", "name": "VR17-04", "unii": "47LH5FC8FW", "linking_id": "47LH5FC8FW", "ref_pname": "VR17-04", "substance_class": "reference" } }, { "uuid": "f26d9e58-b7ee-4007-8bef-fe53b85229cd", "amount": { "uuid": "1b27592e-1200-475f-a9f5-a1ba7b8b1ba4" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "9794be32-b9ee-480c-a06c-b693da1dc950" ], "related_substance": { "uuid": "962e9d8f-dad7-4cf3-9355-c13bcd2dd85e", "refuuid": "69c65d2a-81a2-4a7d-99fa-f6ac61b7d767", "name": "NEPUVIBART", "unii": "2G8MNM5LHS", "linking_id": "2G8MNM5LHS", "ref_pname": "NEPUVIBART", "substance_class": "reference" } }, { "uuid": "56b45569-f389-4923-8cef-410c8a8a467e", "amount": { "uuid": "4f02901b-ccb1-4ef4-b915-f194521d6756" }, "type": "VACCINE ANTIGEN->TARGET", "references": [ "b1c42e05-ac07-4e7b-b79b-48045ce257d0" ], "related_substance": { "uuid": "c287197b-24f7-4c32-a724-7c848cef6436", "refuuid": "a86eb376-d258-9e3e-9125-61223a9c50b2", "name": "BBV-152 ANTIGEN", "unii": "76JZE5DSN6", "linking_id": "76JZE5DSN6", "ref_pname": "BBV-152 ANTIGEN" } }, { "uuid": "2c9eefc3-6c13-44ac-9a55-68d240b3fecc", "amount": { "uuid": "fcb66782-e0cb-49a0-9122-3a93b99daf7d" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "78b2b7ac-0135-4110-88e2-d43a93e8bfcd" ], "related_substance": { "uuid": "2989b4c7-d8eb-4637-9e55-587442fc06ab", "refuuid": "9894ae0f-23b0-4819-98a3-0556ed3b1ac9", "name": "Ensitrelvir", "unii": "PX665RAA3H", "linking_id": "PX665RAA3H", "ref_pname": "Ensitrelvir" } }, { "uuid": "d947ac24-7c8f-4a6e-a3b6-dbe157b89d97", "amount": { "uuid": "8bdbfc30-1b5d-4e6d-b914-ac4fdddd8691", "average": 694, "units": "NANOMOLAR" }, "comments": "Epithelial Vero E6 cells; EC50 Nirmatrelvir = 74.5", "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "f4cbc0d7-fd0f-41d1-a4ae-f4df069b9b46", "refuuid": "b6e0f6f1-dc96-4357-8ff0-a7f73e0f8338", "name": "PF-07329268", "unii": "5C2EJ8H89M", "linking_id": "5C2EJ8H89M", "ref_pname": "PF-07329268", "substance_class": "reference" } }, { "uuid": "0b920d6d-f31a-4400-92b9-06d3a7b6ce4e", "amount": { "uuid": "fbf0babb-a926-4a25-8063-1d71e097093e" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "2f50f269-aef6-42cf-8429-f4b9c2fe5ec3" ], "related_substance": { "uuid": "d6aca225-9599-4f5f-a3a4-84099c557432", "refuuid": "457c6e3e-6e3f-4b97-8dbc-75937df85299", "name": "BRILACIDIN", "unii": "I1679X069H", "linking_id": "I1679X069H", "ref_pname": "BRILACIDIN", "substance_class": "reference" } }, { "uuid": "69c66221-c155-4339-888f-efd37574fe28", "amount": { "uuid": "09ede3a5-e546-474d-8bcc-4e578a40b166" }, "type": "VACCINE ANTIGEN->TARGET", "references": [ "2978b9eb-57f8-4401-99bb-3dba044fb8c6" ], "related_substance": { "uuid": "76c6c979-82c7-4119-bc3d-06c74ad7133c", "refuuid": "7c1c03f6-ff6b-447f-9425-990059eb88c5", "name": "Zeldesmeran", "unii": "BD2KE88JH4", "linking_id": "BD2KE88JH4", "ref_pname": "Zeldesmeran", "substance_class": "reference" } }, { "uuid": "f75cf966-9b11-4b2a-a6e3-e3808979e5ac", "amount": { "uuid": "07f163a0-8bb1-4c90-8b5a-fe28bf5a5eba" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "1d53fb8b-cafc-43c0-86d9-c6c423597038" ], "related_substance": { "uuid": "563b3bab-6adf-4d1a-a89a-b703261971bb", "refuuid": "f261c3f4-24d3-482e-805f-958cb4d1089f", "name": "Famtozinameran", "unii": "JSV288Q5CV", "linking_id": "JSV288Q5CV", "ref_pname": "Famtozinameran", "substance_class": "reference" } }, { "uuid": "27ca2dc7-c42b-44cf-a56e-d4fd986d6e74", "amount": { "uuid": "50705ed1-65da-4fc9-808c-863687ac910f" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "3a83d6af-24e5-4ef9-9095-060b4c566099" ], "related_substance": { "uuid": "9d8b724d-42da-4c0b-a6af-6e0dd89260b3", "refuuid": "e9c1fe81-dcd1-4386-82d1-b1f9b1ca2268", "name": "Gorivitug", "unii": "83DC7W9PBC", "linking_id": "83DC7W9PBC", "ref_pname": "Gorivitug", "substance_class": "reference" } }, { "uuid": "4b435431-bf7a-4c42-8802-f0a1e0ed4f79", "amount": { "uuid": "517e4049-1117-496c-8791-33ced0299b69" }, "type": "INHIBITOR->TARGET", "related_substance": { "uuid": "567d1eb0-1a3a-4ae0-af5a-f221f768d963", "refuuid": "b04ecc09-83fe-4c25-9dcc-d362648ef076", "name": "Imelasomeran", "unii": "5295LF55B6", "linking_id": "5295LF55B6", "ref_pname": "Imelasomeran", "substance_class": "reference" } }, { "uuid": "b2e5f186-ca45-4ba1-bb44-f3dc02c55a54", "amount": { "uuid": "85131203-bd21-4ce4-8daa-9f2cf93b3557" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "2617629b-e412-4115-9b1b-5dc00e923647" ], "related_substance": { "uuid": "7c0e4878-0de9-4015-88f8-63021e6112da", "refuuid": "40c429f5-a337-4a10-b8ae-1e0674478ddb", "name": "JNJ-5207852", "unii": "4I9OVB1G7D", "linking_id": "4I9OVB1G7D", "ref_pname": "JNJ-5207852", "substance_class": "reference" } }, { "uuid": "ea2ec604-cf68-4ca8-a5ed-447d8c870112", "amount": { "uuid": "77e3d989-c10c-40c6-891d-ab8d5130d27a" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "1460efb8-e8a2-4b9d-b34f-225e575ce26f" ], "related_substance": { "uuid": "b5aacd9c-e31c-4f0b-ac6a-cf217e16ef87", "refuuid": "3a8cb524-d48f-4621-a940-6f91e5adcac6", "name": "ENSOVIBEP", "unii": "PV6AA88RDU", "linking_id": "PV6AA88RDU", "ref_pname": "ENSOVIBEP" } }, { "uuid": "dd0d99f6-4bcf-4450-989e-7b725d6709cd", "amount": { "uuid": "ea03fed9-b7a6-4be4-b539-32b64f5bbad3" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "72940031-6c34-4b34-8208-43c8d74550a9" ], "related_substance": { "uuid": "3212b253-454b-4d9f-9e76-3bb9408e3e88", "refuuid": "b1206f22-0660-4789-824a-00e2f18f77f6", "name": "MASAVIBART", "unii": "6ZH4JN5VVR", "linking_id": "6ZH4JN5VVR", "ref_pname": "MASAVIBART", "substance_class": "reference" } }, { "uuid": "867f25e8-72fd-4c70-8e4c-44cb075c4d6e", "amount": { "uuid": "c43ddf63-626e-4a10-b862-3f31bf0143a9" }, "type": "INFRASPECIFIC->PARENT ORGANISM", "references": [ "8e3f264d-8eae-4337-a0cd-898976ac021c", "0710f873-4787-4d15-8408-3858816e9ea9" ], "related_substance": { "uuid": "68455400-42d7-4318-85ba-4a7c7f50ffdb", "refuuid": "d6c71e5d-f866-4d9f-a5ca-c9de6a3b809f", "name": "SARS-COV2 B.1.1.529 VARIANT", "unii": "VV9NW7QG2X", "linking_id": "VV9NW7QG2X", "ref_pname": "SARS-COV2 B.1.1.529 VARIANT", "substance_class": "reference" } }, { "uuid": "761a9468-ebc7-4b3e-ab31-38a95cfeddc4", "amount": { "uuid": "93d2eaaf-ad78-488d-8405-28b12f6044e2" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "30a08f14-1357-468a-b459-aae225b85399" ], "related_substance": { "uuid": "813b9ec6-63df-4368-a32e-c549722ebd93", "refuuid": "4b090c3c-cdb6-4143-af2f-34acfd2d830b", "name": "DVX-201", "unii": "YU2RGF2APH", "linking_id": "YU2RGF2APH", "ref_pname": "DVX-201", "substance_class": "reference" } }, { "uuid": "f8d422da-27d9-4505-9f43-5bc27f9931b5", "amount": { "uuid": "4fbcf559-4f1d-4582-92c6-f10af3488bba" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "b13c9582-b946-4f50-80be-ef8af07bb658" ], "related_substance": { "uuid": "183bcfd2-a3e8-4a6c-b373-a25513c41c0a", "refuuid": "f9bc8d72-ad76-83a2-8352-f55a6ef0fd55", "name": "AD5-NCOV", "unii": "5AHC3V2UQS", "linking_id": "5AHC3V2UQS", "ref_pname": "AD5-NCOV" } }, { "uuid": "696f20d2-a3b2-44da-9681-f8ee81126852", "amount": { "uuid": "693d6def-7bf1-4e96-bca4-30bd7e811558" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "06bb5806-c139-481b-a4ed-8fab74620b39" ], "related_substance": { "uuid": "1e656e91-3489-4d00-81e1-117a2f588003", "refuuid": "1e7d823a-4e49-4c20-99ef-ac8ce3f6bea3", "name": "RIMTERAVIMAB", "unii": "Z4LZB5VCU4", "linking_id": "Z4LZB5VCU4", "ref_pname": "RIMTERAVIMAB" } }, { "uuid": "b6eb5ada-2bfd-4932-a0c1-a03643ef39cf", "amount": { "uuid": "209e1597-ac53-4d20-a010-e2f9af936fa2" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "43c7eaca-3671-4cb6-b5fc-4a04f5d895a9" ], "related_substance": { "uuid": "1e437f27-5515-4cbd-8f90-6687da30db41", "refuuid": "30e5373c-8f85-4e29-bc18-30f8a5db12e4", "name": "GENZ-123346", "unii": "8JW4ZYR2CT", "linking_id": "8JW4ZYR2CT", "ref_pname": "GENZ-123346", "substance_class": "reference" } }, { "uuid": "1212e07e-09d8-429c-aba9-ac751414db81", "amount": { "uuid": "f16f9881-23a0-433e-9dab-f4a084fb3610" }, "type": "VACCINE ANTIGEN->TARGET", "related_substance": { "uuid": "463b3822-f9cc-4880-acd6-864bf0efb0dd", "refuuid": "e07e474c-4ab9-4ad6-8452-e78ecf779193", "name": "CIGB-66", "unii": "N49R9D9AFB", "linking_id": "N49R9D9AFB", "ref_pname": "CIGB-66", "substance_class": "reference" } }, { "uuid": "314d18bd-6954-4b22-9bed-6f2041b01673", "amount": { "uuid": "7022e8ee-7f4a-4cba-b4e5-67be071e6b2c" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "edd21630-67fa-44c9-865d-ba342743bafe" ], "related_substance": { "uuid": "5b79a39e-5678-4b6a-ad12-bcb8dfaf919f", "refuuid": "de824f40-fa1a-43f8-8168-fb46669a9941", "name": "SARS-COV2", "unii": "B6L4N5Z4GH", "linking_id": "B6L4N5Z4GH", "ref_pname": "SARS-COV2", "substance_class": "reference" } }, { "uuid": "5365911e-4d08-46e9-9b15-0761c876d81a", "amount": { "uuid": "79a2cd8b-c2e9-4960-b1da-1367d7fc5d81" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "related_substance": { "uuid": "00de312d-154b-4f6f-9a7d-d48f117c16df", "refuuid": "c3283f8f-4d42-40a3-9bb0-c1de995aacf2", "name": "Carocovatein", "unii": "2V3ZF46GMQ", "linking_id": "2V3ZF46GMQ", "ref_pname": "Carocovatein" } }, { "uuid": "9250ecdd-f50f-41ec-9226-ab05ea1b0c57", "amount": { "uuid": "3499b835-865f-4126-8135-737a9aef6061", "average": 181, "units": "NANOMOLAR" }, "comments": "Differentiated normal human bronchial epithelial (dNHBE) cells", "qualification": "EC90", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "08cd1275-63dc-48c4-9886-10d0349c098d" ], "related_substance": { "uuid": "fa788f54-8f9a-49e1-a67a-58957b71e604", "refuuid": "c028f347-7022-4164-ae58-1d65bd28fa6b", "name": "Nirmatrelvir", "unii": "7R9A5P7H32", "linking_id": "7R9A5P7H32", "ref_pname": "Nirmatrelvir" } }, { "uuid": "4c00305f-c93d-4d1d-90fb-c876f11a5780", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "4f6daf48-df8f-4f6f-96c8-190bdce6b57a" ], "related_substance": { "uuid": "65fe79db-2385-4eec-a983-41d8fc22fb99", "refuuid": "4c0db7df-38d9-672b-e066-2f8159f6aa5f", "name": "INM-005", "unii": "QJ4WJD8DD3", "linking_id": "QJ4WJD8DD3", "ref_pname": "INM-005" } }, { "uuid": "0d70d89e-1a7b-4996-b62f-245e4fb44c6b", "amount": { "uuid": "31f5c6a0-38bc-40fd-a8d7-00b520064a71", "type": "Site Range", "high": 100, "low": 50.65, "units": "%" }, "comments": "On February 5, 2021 Sinovac announced data from a 12,396-participant, Phase III trial in Brazil and Turkey showing CoronaVac to be 100% effective in preventing death or hospitalization in patients with COVID-19, 83.7% effective in avoiding cases that required any medical treatment, but just 50.65% effective at preventing infection with the virus. ", "qualification": "EFFICACY", "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "4855e6ff-66b2-4c62-95a6-6a1eea0d2cd1" ], "related_substance": { "uuid": "759e309d-f33a-4db1-8ad9-e222e8164e1a", "refuuid": "efeb7a77-ee1a-4dad-aec8-3a4b6ab1b5c4", "name": "CORONAVAC ANTIGEN ADJUVATED WITH ALUM", "unii": "QU5NBP9XL3", "linking_id": "QU5NBP9XL3", "ref_pname": "CORONAVAC ANTIGEN ADJUVATED WITH ALUM" } }, { "uuid": "ab8336d8-e3e1-4f55-a632-9b5afe9c09ea", "amount": { "uuid": "5717c3b0-73ac-4a32-af24-4506a743fe12", "average": 95, "units": "%" }, "comments": "From 7 days after second dose to a median time of 2 months.", "qualification": "EFFICACY", "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "3c44f2c2-268a-4f09-b0c1-9f2aca8208ff", "fb3e03bd-017a-40ae-9c55-40056da5af33" ], "related_substance": { "uuid": "2648ca6c-409a-44e6-8741-97f76c1fb26d", "refuuid": "6fefa717-6a4c-435f-a692-46189283764f", "name": "Tozinameran", "unii": "5085ZFP6SJ", "linking_id": "5085ZFP6SJ", "ref_pname": "Tozinameran" } }, { "uuid": "28033015-61ae-43b6-9e8a-b7b8fe31c058", "amount": { "uuid": "99b1096e-226c-41c3-8d79-033d5e0819f4" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "e6f885ef-c296-4895-b380-58ffee1051a8" ], "related_substance": { "uuid": "2cd07573-3fa3-4392-96cd-b3dff401d004", "refuuid": "cf340e37-0b69-4dc6-a8e8-1eb019cc5fd6", "name": "ADINTREVIMAB", "unii": "054Q5D7VZI", "linking_id": "054Q5D7VZI", "ref_pname": "ADINTREVIMAB" } }, { "uuid": "34550e37-52f5-4bec-b3de-ac1ba2a5ab19", "amount": { "uuid": "415791a9-dc51-45a7-bc8c-e3a4cd836fc4" }, "type": "INHIBITOR->TARGET ORGANISM", "interaction_type": "IN-VITRO", "related_substance": { "uuid": "0e9e8a25-f264-4acb-8ab9-83163453f3b7", "refuuid": "e6da06a8-9bed-4b1a-b1f1-682609997bd4", "name": "UPANOVIMAB", "unii": "8E88WSA6X3", "linking_id": "8E88WSA6X3", "ref_pname": "UPANOVIMAB" } }, { "uuid": "5d2cb019-3e22-43f7-8feb-301c3f15f08b", "amount": { "uuid": "fb8b9365-6cdd-486d-bd78-6212d867e65b" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "1ca92f5e-92c1-456e-adba-8a8956c372fb" ], "related_substance": { "uuid": "06e4c404-4246-40ce-b9e2-1971c5e01b7e", "refuuid": "9237705b-118d-44d4-8571-7449b97f87b8", "name": "RIAMILOVIR", "unii": "F2HTG1MH2D", "linking_id": "F2HTG1MH2D", "ref_pname": "RIAMILOVIR", "substance_class": "reference" } }, { "uuid": "ca4d9ffc-a9c7-402a-b831-278051e33637", "amount": { "uuid": "12401b13-036d-4338-8f71-75f158be9170" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "f28a5c92-2094-4f43-a821-a1e9873e6d37" ], "related_substance": { "uuid": "08ae8689-54e2-428f-abc0-7d4e5e38d091", "refuuid": "19633177-e160-b0b8-31fc-0123c989ebfc", "name": "ABDAVOMERAN", "unii": "JV8KBX6XZG", "linking_id": "JV8KBX6XZG", "ref_pname": "ABDAVOMERAN", "substance_class": "reference" } }, { "uuid": "5e845c71-adca-456e-91d5-05c1172c82f8", "amount": { "uuid": "7f52c83e-25e3-4c17-8b70-05bc22b1c85f" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "680418f0-108e-40dc-a3e7-1d116c63ab40" ], "related_substance": { "uuid": "b14b8bc0-260a-400d-853b-d3e30abdc192", "refuuid": "e470e0fb-6e29-43bf-97fd-7e97fe67ece4", "name": "ABIMTRELVIR", "unii": "X86ZM6S3TQ", "linking_id": "X86ZM6S3TQ", "ref_pname": "ABIMTRELVIR", "substance_class": "reference" } }, { "uuid": "1f88210e-81e7-4046-bf64-376878dad44a", "amount": { "uuid": "9c81828d-1537-4e48-8c07-c49e3b662304" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "2cc1f31c-e926-4291-829a-7da30c7640c4" ], "related_substance": { "uuid": "04995a36-0f08-4cd4-b003-d48794c89cb6", "refuuid": "1ffe93dd-bd69-4bda-9d09-1a05c8e5d227", "name": "VIXICOVTOGENE OBOPLASMID", "unii": "FA9G2YWR23", "linking_id": "FA9G2YWR23", "ref_pname": "VIXICOVTOGENE OBOPLASMID", "substance_class": "reference" } }, { "uuid": "e7227b0e-230e-48f3-bd42-7b4d55e5e29f", "amount": { "uuid": "ad86d254-96a4-4dfe-9a3a-663ea61cdfe0" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "e49c3a39-78b0-4bc8-9fec-016e80f6ea9e" ], "related_substance": { "uuid": "8ea93e9c-bb24-4acb-99b7-bf8b26c32203", "refuuid": "a0ebd42d-a9ca-499a-84d1-eb3d4b3c22dc", "name": "N4-HYDROXYCYTIDINE", "unii": "C3D11PV2O4", "linking_id": "C3D11PV2O4", "ref_pname": "N4-HYDROXYCYTIDINE", "substance_class": "reference" } }, { "uuid": "1ba9df4e-fe67-44a7-986e-c1253374888c", "amount": { "uuid": "e537df48-9118-4360-884e-803927a64db0" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "3456bc04-7ee6-4ad3-9d40-0f50277d9792" ], "related_substance": { "uuid": "204e27d6-818a-4f74-9090-8d816b7a45e8", "refuuid": "e4af6f54-8ac5-4c3a-8e2e-f40c0bd08185", "name": "Deuremidevir des-triisobutryl", "unii": "LG6V8A3GKN", "linking_id": "LG6V8A3GKN", "ref_pname": "Deuremidevir des-triisobutryl", "substance_class": "reference" } }, { "uuid": "361a0704-4e74-4cbd-ae3b-212ca0868257", "amount": { "uuid": "52bea2d1-9500-4594-b181-72fd571c773d", "average": 34, "high": 43, "low": 25, "units": "NANOMOLAR" }, "qualification": "EC50", "type": "INHIBITOR->TARGET ORGANISM", "references": [ "f4297f7c-3f7d-4b39-a311-e575eaaaca52" ], "related_substance": { "uuid": "1cb92614-a738-4125-ae32-005cf023faea", "refuuid": "15ffc001-59c6-4052-90e6-e0b895118abb", "name": "Simnotrelvir", "unii": "R4QFU2UR3K", "linking_id": "R4QFU2UR3K", "ref_pname": "Simnotrelvir", "substance_class": "reference" } }, { "uuid": "42e022df-7c76-45dc-84ff-077e5b33def6", "amount": { "uuid": "b71aa786-de71-41ad-9fa8-2651ae724354" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "d3488c4e-94ff-42d1-b88c-9a1337037a51" ], "related_substance": { "uuid": "2d8489c1-8495-4ddb-870a-a693077ce6b5", "refuuid": "8eaac61d-12d6-4465-b23b-545fc3945ba2", "name": "MERAFLOXACIN", "unii": "G6U51T1K77", "linking_id": "G6U51T1K77", "ref_pname": "MERAFLOXACIN", "substance_class": "reference" } }, { "uuid": "8cbdd4a8-5e16-4619-8e39-bed58f52cbef", "amount": { "uuid": "3c057210-2f20-444a-af17-ebc51e466431" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "2e3f2b25-8ac4-4f5c-864d-8ca308417246", "refuuid": "51774594-23d1-4cce-9aa5-510e23052381", "name": "RM-4848", "unii": "RGV27LC2Y8", "linking_id": "RGV27LC2Y8", "ref_pname": "RM-4848", "substance_class": "reference" } }, { "uuid": "8c096c98-5c62-409b-a79d-af14c600e2c5", "amount": { "uuid": "18789274-a360-4694-a64d-695b86b6c715" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "related_substance": { "uuid": "15f12456-e14f-4f41-abd3-2ba2b7f40b58", "refuuid": "fb5b8b9f-4eb8-4811-9ad5-8aa42df21bf4", "name": "CX-036651", "unii": "64GK6D44AB", "linking_id": "64GK6D44AB", "ref_pname": "CX-036651", "substance_class": "reference" } }, { "uuid": "34fee6fa-4fab-4bda-8ce0-8f69217324d5", "amount": { "uuid": "917af0a8-bc0e-436f-8a82-450a49c869df" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "bc22e3b9-0721-46f9-a39a-ddaf8eaf7911" ], "related_substance": { "uuid": "1d0c5d32-65b5-433f-a51e-90bd6a4a83e1", "refuuid": "406750f3-9f1d-428b-8d3f-d6debfff721c", "name": "CX-037073", "unii": "89K3MV8294", "linking_id": "89K3MV8294", "ref_pname": "CX-037073", "substance_class": "reference" } }, { "uuid": "e1c0bbf2-61a3-4866-a678-94062ba3a505", "amount": { "uuid": "71633d66-9b8d-489f-a69e-47065bf3dda6" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "c9b6b858-06a0-458a-bb7a-1623ccafa172" ], "related_substance": { "uuid": "34a2303f-4f3c-4c25-a532-57afed94c185", "refuuid": "9b04147e-bd05-41b1-b37e-30a7d14513c1", "name": "NAFAMOSTAT", "unii": "Y25LQ0H97D", "linking_id": "Y25LQ0H97D", "ref_pname": "NAFAMOSTAT", "substance_class": "reference" } }, { "uuid": "169bbea1-af67-4cfa-a13f-88a7c28bcdf4", "amount": { "uuid": "31b4081d-71b6-4d72-8b79-b0a49fcac275" }, "type": "INHIBITOR->TARGET ORGANISM", "related_substance": { "uuid": "74031ce3-90f3-4818-af19-986e1b89cc28", "refuuid": "eddf7f4e-f2b6-4059-9702-a1a9b2b847a5", "name": "Talovirtide", "unii": "JS929A2LKC", "linking_id": "JS929A2LKC", "ref_pname": "Talovirtide", "substance_class": "reference" } }, { "uuid": "23827093-b2fa-4f49-8ea0-72c4f4c61c0b", "amount": { "uuid": "e652fc82-dd4b-468f-9f78-47b8067daffe" }, "type": "GENE MODIFIED PROTEIN->TARGET ORGANISM", "references": [ "c8a48031-06b7-47fb-b6c8-e88b1b238519" ], "related_substance": { "uuid": "b8959634-d972-4290-92dc-dd2d57c98016", "refuuid": "4c4c3173-2dc2-4be4-83c4-15bffcba7f96", "name": "Pitozinameran", "unii": "8VLF8J3FR3", "linking_id": "8VLF8J3FR3", "ref_pname": "Pitozinameran", "substance_class": "reference" } }, { "uuid": "88d4ecf8-a4f2-4e81-8171-628dc57dd113", "amount": { "uuid": "f579a853-8c18-4ff5-a381-b3204b709dc2" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "d2f3a49c-1b1d-47e7-b55c-2a8003374e20" ], "related_substance": { "uuid": "233e2478-10ab-430d-8b6a-5c8ba61d0c63", "refuuid": "12e9af0a-41e6-46cb-9738-60f561c77af0", "name": "Raxtozinameran", "unii": "N36VHK46PR", "linking_id": "N36VHK46PR", "ref_pname": "Raxtozinameran", "substance_class": "reference" } }, { "uuid": "3ffef3f5-b33d-4bef-9a41-e04484e67b70", "amount": { "uuid": "de16fb86-d1f8-4a30-a171-d80398e72a3f" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "1374dd52-5660-424c-b17a-3d9e713193ac" ], "related_substance": { "uuid": "9ae72d8e-eac3-4754-a301-93def962e984", "refuuid": "d2c690c7-ac90-408f-b7e9-5e89227f6999", "name": "Upalsecovatein", "unii": "RBJ7D8ZH4X", "linking_id": "RBJ7D8ZH4X", "ref_pname": "Upalsecovatein", "substance_class": "reference" } }, { "uuid": "aec05faa-580b-4a0f-be01-f58cb8504b70", "amount": { "uuid": "14cd7b41-40e1-4802-9c17-0fd71048d711" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "0c30b72f-a1f3-42dc-b4bc-a68a2f74ecd8" ], "related_substance": { "uuid": "089755e7-c12f-4da4-9858-abdc7eb7b067", "refuuid": "8ec1f50b-a98c-4c45-ac2f-3e2c51d5bbe4", "name": "Deunirmatrelvir", "unii": "CC7MR4XE6T", "linking_id": "CC7MR4XE6T", "ref_pname": "Deunirmatrelvir", "substance_class": "reference" } }, { "uuid": "1106fe75-a2f0-46dd-aa4d-32bc6053d93b", "amount": { "uuid": "7c51989d-18bb-479b-880b-76ceed18a453" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "00102b98-470c-42d2-b766-a0cd661d5080" ], "related_substance": { "uuid": "dfae284b-39a8-415c-95ba-9f9ab591fa78", "refuuid": "409ea4fe-1887-4e33-ab17-61f0af373a18", "name": "Timcevibart", "unii": "P45RTW33K4", "linking_id": "P45RTW33K4", "ref_pname": "Timcevibart", "substance_class": "reference" } }, { "uuid": "db21d394-6ce2-4dc0-b516-9ef9c15b9306", "amount": { "uuid": "45e72967-77ea-4ca1-9396-23adccdf2f4c" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "0ccf9dd0-4811-4c7c-8faa-94db6e43e24e" ], "related_substance": { "uuid": "e385833e-52ce-4c8e-886d-17300762555c", "refuuid": "4a354c49-c449-449a-925f-cf927fe79c7c", "name": "ELASOMERAN", "unii": "EPK39PL4R4", "linking_id": "EPK39PL4R4", "ref_pname": "ELASOMERAN", "substance_class": "reference" } }, { "uuid": "ff6bb6cb-a46e-4cb8-af08-81f4f01b00e3", "amount": { "uuid": "85893592-5fdd-48ec-beeb-0cd59bbf220c" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "32518bf5-739a-404b-ba91-9f9afff79213" ], "related_substance": { "uuid": "4c6b99ec-35fb-45f6-8244-53bc40bd8538", "refuuid": "4127dad7-8ef7-48c4-a4c7-a3867935f28f", "name": "RUPINTRIVIR", "unii": "RGE5K1Q5QW", "linking_id": "RGE5K1Q5QW", "ref_pname": "RUPINTRIVIR", "substance_class": "reference" } }, { "uuid": "3181b14b-dc85-4667-8477-9fe3c208f827", "amount": { "uuid": "1c82e605-2c9a-456f-96e1-c158da9c884f" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "acc37f84-4962-4734-b42a-52b2d605897d" ], "related_substance": { "uuid": "f90b71ba-a8de-495a-b699-75cf0e48cc6f", "refuuid": "845f8cb9-e635-47fd-8265-2c68e32a842c", "name": "Vecilmeran", "unii": "28PLX9696B", "linking_id": "28PLX9696B", "ref_pname": "Vecilmeran", "substance_class": "reference" } }, { "uuid": "9163ff3a-a3ec-49ce-ac29-1f64861eb88c", "amount": { "uuid": "d8f8935d-2525-4d22-991b-360cccd4ddf1" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "b96506c7-98cb-41ea-b923-48b88816bd8c" ], "related_substance": { "uuid": "61922657-ce2c-49e7-a2c5-a1744d45f66f", "refuuid": "4781a4cd-258a-4e8e-8a9b-21620e6ae03c", "name": "Velucovacap", "unii": "54HU9J47SF", "linking_id": "54HU9J47SF", "ref_pname": "Velucovacap", "substance_class": "reference" } }, { "uuid": "c4a122de-4d2f-4f76-8445-275c5cfbe61a", "amount": { "uuid": "c32afdd5-9705-47a7-a9ab-47a94cbd26d4" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "related_substance": { "uuid": "83b3bb02-3663-41f7-8e35-b7e5a3c115e3", "refuuid": "54260dcf-d280-4d0a-bc69-a274b76f922c", "name": "Andusomeran", "unii": "4F9QRS7ZV2", "linking_id": "4F9QRS7ZV2", "ref_pname": "Andusomeran", "substance_class": "reference" } }, { "uuid": "dc6c54e0-939a-4d08-9f07-c5dae5bb3efa", "amount": { "uuid": "c8a1df00-6c51-4078-881b-7ee0aaa128ec" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "78f97143-6ae0-47ff-85f2-64f5ef047972" ], "related_substance": { "uuid": "d3a6c2e6-635b-4a81-9e34-a11a95a51e1c", "refuuid": "552cc7f6-c624-46fd-97eb-b9618f05495d", "name": "CX-039300", "unii": "LG5UQ83MXK", "linking_id": "LG5UQ83MXK", "ref_pname": "CX-039300", "substance_class": "reference" } }, { "uuid": "fcc3333d-53ec-4022-a707-e849520d94c7", "amount": { "uuid": "11b9c14d-4671-408d-b31e-1edc527d4a96" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "8402e05f-61e0-48ca-a5b4-807d4433d114" ], "related_substance": { "uuid": "4d7ec29d-2814-4767-b476-e73e3dd308f7", "refuuid": "d543478c-2e8a-40d7-80e3-784a1c116928", "name": "Vintesomeran", "unii": "3E9P89C6JX", "linking_id": "3E9P89C6JX", "ref_pname": "Vintesomeran", "substance_class": "reference" } }, { "uuid": "e75bb22b-820e-447b-8dac-abe1df59833e", "amount": { "uuid": "1b0e9ea9-a73c-4c12-8bf7-fc2dee447b43" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "67b83ea9-b3a5-40ad-b20d-27d0c3734c2f" ], "related_substance": { "uuid": "f154149c-14a4-4c16-a279-48346383eb0c", "refuuid": "3ec6d818-29f5-491d-bd33-a878daf6ce1a", "name": "Tegrenmeran", "unii": "8JTY7VW9J8", "linking_id": "8JTY7VW9J8", "ref_pname": "Tegrenmeran", "substance_class": "reference" } }, { "uuid": "52c408c5-a724-4f5f-acda-7f6e798d1c4d", "amount": { "uuid": "e14dcde4-6d07-43c8-9124-03fd5173deaa" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "2001f23c-2078-4d24-a1e9-f2e1eb14dd01" ], "related_substance": { "uuid": "7124f7de-a96b-41e7-9751-90ca9df22e5f", "refuuid": "ba5d859a-9fc3-44a1-8bf0-5b49addcb7e0", "name": "Deuremidevir", "unii": "MF2PS6XPS4", "linking_id": "MF2PS6XPS4", "ref_pname": "Deuremidevir", "substance_class": "reference" } }, { "uuid": "cc6a908e-f482-46d6-893b-589cb396d674", "amount": { "uuid": "5b52a311-4236-4dba-b07e-026157ac32d6" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "7c4114ea-4dc9-4d85-bc34-db069f881362" ], "related_substance": { "uuid": "7ae08fa7-7be9-487a-8552-912735f47c04", "refuuid": "8cee9ad1-850c-414a-9b04-6fa5b7f6511e", "name": "Ibramvibart", "unii": "PRC4J48944", "linking_id": "PRC4J48944", "ref_pname": "Ibramvibart", "substance_class": "reference" } }, { "uuid": "47613f56-3d48-4ccf-b29d-cc22467a300a", "amount": { "uuid": "e88bb609-8fb9-4d2a-9cef-23e342973435" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "7cdc583f-827e-4480-9c5d-cbd3be531e12" ], "related_substance": { "uuid": "0b7dbe56-0fc4-4c28-865d-8c90db17c7b6", "refuuid": "70d2a8b5-6dfa-40f2-a087-841ba38e19aa", "name": "Rubravameran", "unii": "LEU6C3Q72D", "linking_id": "LEU6C3Q72D", "ref_pname": "Rubravameran", "substance_class": "reference" } }, { "uuid": "01fe3fc2-dd62-48ca-928a-7887d34de098", "amount": { "uuid": "48aca7f1-5ce2-413e-a702-7cefaf6c6ccf" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "eab52952-1fee-49a0-a284-b971652bd4e4" ], "related_substance": { "uuid": "1c1d0f09-a5fa-4ad5-8667-f3ed4e8b49b8", "refuuid": "0452e9ae-1e61-4d72-a5e2-aefa61a41ca4", "name": "Tagovameran", "unii": "BV8R57Y3YG", "linking_id": "BV8R57Y3YG", "ref_pname": "Tagovameran", "substance_class": "reference" } }, { "uuid": "7c0e1400-110e-439f-b96f-f2893b14f8ef", "amount": { "uuid": "0624a6d3-b02d-41f9-b967-5b843924f664" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "b8c58027-0bad-4121-9f56-ea59c4cfd7cb" ], "related_substance": { "uuid": "5e502be2-a2dc-4e87-87cf-5b954088d06a", "refuuid": "168f6a3a-94c5-4fe1-bdd2-26aacd1412ba", "name": "Girocovatein", "unii": "BAA4CV6ACY", "linking_id": "BAA4CV6ACY", "ref_pname": "Girocovatein", "substance_class": "reference" } }, { "uuid": "2a80f929-0a5d-4fd6-a411-49bd20db64bd", "amount": { "uuid": "117f523c-f623-48a4-8dcd-e9233b56153f" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "related_substance": { "uuid": "9f7de2b0-e6c6-4c6e-a3f4-5e2ee61be84d", "refuuid": "ad914447-a060-4a04-83ed-729e73f043d5", "name": "Cemivameran", "unii": "3W7YFK5FNA", "linking_id": "3W7YFK5FNA", "ref_pname": "Cemivameran", "substance_class": "reference" } }, { "uuid": "755ecf3f-11d8-4f3a-b219-c62c034883e2", "amount": { "uuid": "61ae6dd8-52ea-4332-ab6d-b282a77c91ba" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "2a7cfef9-4181-4095-99ce-1d54a5289a94" ], "related_substance": { "uuid": "c65d44c5-64b5-4e8c-b7a9-1f5ca3d70383", "refuuid": "dedbfaa2-ac00-477e-ae70-e2581ef4e8b0", "name": "Damlecovatein", "unii": "26JP6N8VU6", "linking_id": "26JP6N8VU6", "ref_pname": "Damlecovatein", "substance_class": "reference" } }, { "uuid": "fd4c11fe-29b7-4dc0-a197-43fe7f9428df", "amount": { "uuid": "2f80d0ea-08f0-4d3e-ad8f-7c9978ce2000" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "ba3dc0cb-6561-4218-a374-44c6a162ed08" ], "related_substance": { "uuid": "40a9f38a-3f9a-4bba-8dfd-cfe56860097c", "refuuid": "bb928815-5375-4914-ba12-ed73c3b32c13", "name": "Lonpovameran", "unii": "UY3ACU236M", "linking_id": "UY3ACU236M", "ref_pname": "Lonpovameran", "substance_class": "reference" } }, { "uuid": "09f844c4-3b11-484e-b5b4-78484460fc81", "amount": { "uuid": "728c4a45-42c5-4ad8-a87f-72a6fc9f902a" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "c0ef9b4c-4fb1-4a51-bf89-f1d43f7afd64" ], "related_substance": { "uuid": "54d069db-769d-472e-bb8d-be70af2b0b8e", "refuuid": "c34009fe-dc81-42db-b2bc-4214c697f756", "name": "Bretovameran", "unii": "RWD33VV79C", "linking_id": "RWD33VV79C", "ref_pname": "Bretovameran", "substance_class": "reference" } }, { "uuid": "443a4cf5-b2c2-49d7-aca2-63199a561620", "amount": { "uuid": "c7d81abf-7ffb-4da3-a1d4-0405926b8633" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "related_substance": { "uuid": "48415059-e4ff-4e2f-aec5-895af2c710ed", "refuuid": "b13a1df6-e546-49a1-b9c9-a17827f92a01", "name": "NVX-CoV2705", "unii": "2RLB4T4GW2", "linking_id": "2RLB4T4GW2", "ref_pname": "NVX-CoV2705", "substance_class": "reference" } }, { "uuid": "19cc5c21-4714-4eea-b02b-67ed325cfc38", "amount": { "uuid": "9b806724-04fa-4098-9c90-b7bf8f8d269a" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "64c24cd4-c9da-4d71-a0d4-f57b73ac2d72" ], "related_substance": { "uuid": "b86cbecc-f561-4ab7-b795-ce716c8759e6", "refuuid": "69706023-f96b-44bf-8647-614fd645af9d", "name": "Tisorimcovatein", "unii": "Z3HD5C268T", "linking_id": "Z3HD5C268T", "ref_pname": "Tisorimcovatein", "substance_class": "reference" } }, { "uuid": "60e997bc-7729-46e6-931a-16e7aa6380c9", "amount": { "uuid": "58972d62-2d51-40c1-ad93-51185c65f480" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "related_substance": { "uuid": "bf2c2fab-9c86-47aa-ae99-49ff31dd7969", "refuuid": "8e961baf-4af6-46a8-8087-8362526915c1", "name": "Bemremeran", "unii": "J87X96APT2", "linking_id": "J87X96APT2", "ref_pname": "Bemremeran", "substance_class": "reference" } }, { "uuid": "5f68890a-0baa-4f8c-8db3-09cf232df51b", "amount": { "uuid": "6f90fe99-650f-4477-8c3f-2ad57776ee99" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "c857acb5-6a70-4a0d-8faa-b22e3388a3d6" ], "related_substance": { "uuid": "751bd5ee-03da-4333-9aec-27c96d074217", "refuuid": "14b2c6d7-8f09-4413-b804-40fe1acd0554", "name": "Pesorimcovatein", "unii": "Q3TKB7GHJ4", "linking_id": "Q3TKB7GHJ4", "ref_pname": "Pesorimcovatein", "substance_class": "reference" } }, { "uuid": "e3aa2678-b338-43db-8f8c-31189b4526b5", "amount": { "uuid": "d70d5e49-6210-4ff7-8ebe-5678965b4e1c" }, "type": "INHIBITOR->TARGET ORGANISM", "references": [ "2e91007b-724d-4c86-ae11-64383e01f374" ], "related_substance": { "uuid": "40656480-5706-43e9-8af6-0b895a4d43df", "refuuid": "89025eb6-cf70-4874-8b63-4c9a2aa150a2", "name": "Vebanvibart", "unii": "5TL7E5D6E6", "linking_id": "5TL7E5D6E6", "ref_pname": "Vebanvibart", "substance_class": "reference" } }, { "uuid": "d01e9f1d-785e-4892-81c7-f93b954ae50c", "amount": { "uuid": "73b9e979-8d15-47d0-ad98-07df66640a77" }, "type": "VACCINE ANTIGEN->TARGET ORGANISM", "references": [ "535509ee-7cf9-49fb-b78f-b1ac3ea86446" ], "related_substance": { "uuid": "cc79a5d5-feec-475f-8a23-c1573d1b3614", "refuuid": "7e6cd0fc-8480-438f-ba33-c3ceecb03163", "name": "RNA-101-B815", "unii": "9B9X8JLC3H", "linking_id": "9B9X8JLC3H", "ref_pname": "RNA-101-B815", "substance_class": "reference" } } ], "substance_class": "structurallyDiverse", "names": [ { "uuid": "caec7301-4590-4871-9282-cb907e5ce8fd", "name": "2019-NCOV", "stdName": "2019-NCOV", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "5be80393-b5bb-49c5-b751-ca1d38a471d7" ], "display_name": false }, { "uuid": "0a760fe9-cbb5-406b-a2f7-0bfcc914af74", "name": "COVID-19", "stdName": "COVID-19", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "e684706b-8f38-421e-bbe1-a40e0845423a" ], "display_name": false }, { "uuid": "b346f43e-44ab-4550-9252-e1315e028a38", "name": "SARS-COV-2", "stdName": "SARS-COV-2", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "4b0010b5-bf69-4ef7-9352-902d3da9c441" ], "display_name": false }, { "uuid": "51a382b7-045f-4e55-861a-0e70fe4dcfe0", "name": "SARS-COV-2 VIRUS", "stdName": "SARS-COV-2 VIRUS", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "7c4e30e9-3f28-486c-9932-d9d1d6d55936" ], "display_name": false }, { "uuid": "8403c2e2-bc64-4395-913c-094ea4d8540e", "name": "SARS-COV2", "stdName": "SARS-COV2", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "9fa711d8-c925-464c-93d6-0066bcc5f6a9" ], "display_name": true }, { "uuid": "f172fe2d-9e2d-48d7-bf67-f6acebc088ac", "name": "SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (2019)", "stdName": "SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (2019)", "type": "cn", "languages": [ "en" ], "preferred": false, "references": [ "1812aef1-937f-4b3d-b930-76639adf4d0f" ], "display_name": false } ], "references": [ { "uuid": "2f50f269-aef6-42cf-8429-f4b9c2fe5ec3", "citation": "Hu Y, Jo H, DeGrado WF, Wang J. Brilacidin, a COVID-19 drug candidate, demonstrates broad-spectrum antiviral activity against human coronaviruses OC43, 229E, and NL63 through targeting both the virus and the host cell. J Med Virol. 2022 May;94(5):2188-2200. doi: 10.1002/jmv.27616. Epub 2022 Feb 2. PMID: 35080027; PMCID: PMC8930451.", "url": "https://pubmed.ncbi.nlm.nih.gov/35080027/", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "0d4a6bb3-f186-4d5f-8324-815a49943e3f", "citation": "P126", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl126.pdf?sfvrsn=a37e0953_7&download=true", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8a96518b-1436-4076-858f-769761cdb305", "citation": "https://en.wikipedia.org/wiki/Favipiravir", "url": "https://en.wikipedia.org/wiki/Favipiravir", "doc_type": "WIKI", "public_domain": true }, { "uuid": "63e37b5b-70fa-4ab8-a38d-caff7f54853d", "citation": "GenBank: QHD43415.1", "url": "https://www.ncbi.nlm.nih.gov/protein/1791269089", "doc_type": "NCBI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "4fd7dd60-616b-4770-87a4-3fee23181bfd", "citation": "GenBank: MN908947.3", "url": "https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3", "doc_type": "NCBI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "40ba015c-6e1d-41cf-9437-58afabe7bc5b", "citation": "Wu, F., Zhao, S., Yu, B. et al. A new coronavirus associated with human respiratory disease in China. Nature (2020). https://doi.org/10.1038/s41586-020-2008-3", "url": "https://www.nature.com/articles/s41586-020-2008-3", "doc_type": "JA", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "1812aef1-937f-4b3d-b930-76639adf4d0f", "citation": "https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome-related_coronavirus", "id": "https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome-related_coronavirus", "doc_type": "WIKI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "d4383a4b-0dc2-fbf0-8bf0-99f242c265db", "citation": "cATALOG OF LIFE 2011", "doc_type": "SRS", "public_domain": true, "tags": [ "NOMEN" ] }, { "uuid": "3de32c20-281e-8ad1-c372-1bfa9622e2c0", "citation": "SRS import [J067L6I0TY]", "url": "http://fdasis.nlm.nih.gov/srs/srsdirect.jsp?regno=J067L6I0TY", "doc_type": "SRS", "public_domain": true, "document_date": 1493391233000, "tags": [ "NOMEN" ] }, { "uuid": "4b0010b5-bf69-4ef7-9352-902d3da9c441", "citation": "Gorbalenya, Alexander E. \"Severe acute respiratory syndrome-related coronavirus–The species and its viruses, a statement of the Coronavirus Study Group.\" BioRxiv (2020).", "id": "https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.07.937862.full.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "e684706b-8f38-421e-bbe1-a40e0845423a", "citation": "https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen", "id": "https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "28e7c16c-fd65-4ed0-8924-21aede66e888", "citation": "https://en.wikipedia.org/wiki/Favipiravir", "url": "https://en.wikipedia.org/wiki/Favipiravir", "doc_type": "WIKI", "public_domain": true }, { "uuid": "5be80393-b5bb-49c5-b751-ca1d38a471d7", "citation": "Li, Guangdi, and Erik De Clercq. \"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).\" (2020).", "url": "https://www.nature.com/articles/d41573-020-00016-0", "doc_type": "JA", "public_domain": true }, { "uuid": "6eddcdcb-5b69-4f5e-b022-1020f70e8f17", "citation": "Toots, Mart, et al. \"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.\" Science translational medicine 11.515 (2019).", "url": "https://stm.sciencemag.org/content/11/515/eaax5866.short", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c2046f69-25bf-42a5-9fc3-685188e48e28", "citation": "GenBank: QHD43415.1", "url": "https://www.ncbi.nlm.nih.gov/protein/1791269089", "doc_type": "NCBI", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "74c1580a-87c3-4629-8083-2b37250ec1af", "citation": "GenBank: MN908947.3", "url": "https://www.ncbi.nlm.nih.gov/nuccore/MN908947.3", "doc_type": "NCBI", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "6a14f32b-ae14-4c2a-a7be-5443030c88aa", "citation": "Wu, F., Zhao, S., Yu, B. et al. A new coronavirus associated with human respiratory disease in China. Nature (2020). https://doi.org/10.1038/s41586-020-2008-3", "url": "https://www.nature.com/articles/s41586-020-2008-3", "doc_type": "JA", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "244f3afd-5635-4bbf-a544-f68c256f72b8", "citation": "Amirian, E. Susan, and Julie K. Levy. \"Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses.\" One Health (2020): 100128.", "url": "https://www.sciencedirect.com/science/article/pii/S2352771420300380", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "63288014-e64d-434d-9565-ed5083bb231c", "citation": "Beigel, John H., et al. \"Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.\" The Lancet Infectious Diseases 18.4 (2018): 410-418.", "url": "https://cloudflare-ipfs.com/ipfs/bafykbzaced4xstofs4tc5q4irede6uzaz3qzcdvcb2eedxgfakzwdyjnxgohq/pdfs/2018%20Safety%20and%20tolerability%20of%20a%20novel%2C%20polyclonal%20human%20anti-MERS%20coronavirus%20antibody%20produced%20from%20transchromosomic.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ee652234-3ac8-4977-acab-4b1870323311", "citation": "https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1.full.pdf", "url": "https://www.biorxiv.org/content/10.1101/2020.06.29.178509v1.full.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "9fa711d8-c925-464c-93d6-0066bcc5f6a9", "citation": "https://www.astrazeneca.com/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html", "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "fa877105-f095-46b5-9321-b911b0c757f1", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "545483c7-e967-47df-b041-70c0d753a504", "citation": "Xia S, Duan K, Zhang Y, et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. Published online August 13, 2020. doi:10.1001/jama.2020.15543", "url": "https://jamanetwork.com/journals/jama/fullarticle/2769612", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "9fd55f89-dbd1-48dc-b3e3-d4426105c6fe", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "de23010a-ce00-4910-84ec-9395c0fcb53b", "citation": "Gao, Qiang, et al. \"Development of an inactivated vaccine candidate for SARS-CoV-2.\" Science (2020).", "url": "https://science.sciencemag.org/content/369/6499/77.abstract", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "d342f30b-5d15-29c4-77e4-ef4762172e60", "citation": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "url": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "doc_type": "JA", "public_domain": true }, { "uuid": "916dba37-8230-4dd4-ad22-ad74d3c0d057", "citation": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "url": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "doc_type": "JA", "public_domain": true }, { "uuid": "a9672f40-bcfe-4eab-bfbe-08b08f82f50d", "citation": "fda_srs", "doc_type": "SRS", "public_domain": true }, { "uuid": "233f7d0b-36ee-45cd-be63-48012d83baac", "citation": "Roback, John D., and Jeannette Guarner. \"Convalescent Plasma to Treat COVID-19: Possibilities and Challenges.\" JAMA.", "url": "https://jamanetwork.com/journals/jama/fullarticle/2763982", "doc_type": "JA", "public_domain": true }, { "uuid": "ac820103-a60a-62a3-4bc4-6de6cebd2d63", "citation": "https://www.pharmaceutical-technology.com/news/german-researchers-covid-19-drug/", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "f2f58432-563b-411e-8e22-226f7de051c8", "citation": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "url": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "doc_type": "JA", "public_domain": true }, { "uuid": "5a172461-a97b-49d2-83e8-81a93adb50c5", "citation": "Müller C, Obermann W, Karl N, Wendel HG, Taroncher-Oldenburg G, Pleschka S, Hartmann RK, Grünweller A, Ziebuhr J. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo. Antiviral Res. 2021 Feb;186:105012. doi: 10.1016/j.antiviral.2021.105012. Epub 2021 Jan 8. PMID: 33422611; PMCID: PMC7791309.", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "43c7eaca-3671-4cb6-b5fc-4a04f5d895a9", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "ba8c3a23-62c9-471d-99e6-bb8274fae69a", "citation": "Toots, Mart, et al. \"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia.\" Science translational medicine 11.515 (2019).", "url": "https://stm.sciencemag.org/content/11/515/eaax5866.short", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8e3f264d-8eae-4337-a0cd-898976ac021c", "citation": "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern", "url": "https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern", "doc_type": "WEB PAGE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "0710f873-4787-4d15-8408-3858816e9ea9", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "72940031-6c34-4b34-8208-43c8d74550a9", "citation": "P126", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "dadee58d-cee4-4682-8a69-98915b665293", "citation": "P126", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl126.pdf?sfvrsn=a37e0953_7&download=true", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "30a08f14-1357-468a-b459-aae225b85399", "citation": "Jeyaraman M, Muthu S, Bapat A, Jain R, Sushmitha ES, Gulati A, Channaiah Anudeep T, Dilip SJ, Jha NK, Kumar D, Kesari KK, Ojha S, Dholpuria S, Gupta G, Dureja H, Chellappan DK, Singh SK, Dua K, Jha SK. Bracing NK cell based therapy to relegate pulmonary inflammation in COVID-19. Heliyon. 2021 Jul;7(7):e07635. doi: 10.1016/j.heliyon.2021.e07635. Epub 2021 Jul 21. PMID: 34312598; PMCID: PMC8294777.", "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294777/", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "edd21630-67fa-44c9-865d-ba342743bafe", "citation": "Beigel, John H., et al. \"Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.\" The Lancet Infectious Diseases 18.4 (2018): 410-418.", "url": "https://cloudflare-ipfs.com/ipfs/bafykbzaced4xstofs4tc5q4irede6uzaz3qzcdvcb2eedxgfakzwdyjnxgohq/pdfs/2018%20Safety%20and%20tolerability%20of%20a%20novel%2C%20polyclonal%20human%20anti-MERS%20coronavirus%20antibody%20produced%20from%20transchromosomic.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "7031cabe-44f7-4182-9a87-e42ef220be01", "citation": "P126", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "2cc1f31c-e926-4291-829a-7da30c7640c4", "citation": "P126", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl126.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5da3a666-603a-4b97-9787-c24142df810a", "citation": "Schäfer, Alexandra, et al. \"Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.\" bioRxiv (2021).", "url": "https://pubmed.ncbi.nlm.nih.gov/34545367/", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "2617629b-e412-4115-9b1b-5dc00e923647", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "441af35e-932e-42e3-8cc9-c5b0e1432c82", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "9794be32-b9ee-480c-a06c-b693da1dc950", "citation": "P126", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl126.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "502c9214-4470-4628-8213-26093592ba8e", "citation": "COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020)", "url": "https://sorrentotherapeutics.com/research/covid-19/covi-amg/", "doc_type": "MANUFACTURER PRODUCT DESCRIPTION", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "bfc52397-de39-4e17-97a5-cd15fb05ad9e", "citation": "Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases George Stamatakis, Martina Samiotaki, Anastasia Mpakali, George Panayotou, and Efstratios Stratikos Journal of Proteome Research 2020 19 (11), 4398-4406 DOI: 10.1021/acs.jproteome.0c00457 ", "url": "https://pubs.acs.org/doi/pdf/10.1021/acs.jproteome.0c00457", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "bb15498a-d3cb-427c-b5a0-5b2617ffb941", "citation": "Wang, C., Li, W., Drabek, D. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun 11, 2251 (2020). https://doi.org/10.1038/s41467-020-16256-y", "url": "https://www.nature.com/articles/s41467-020-16256-y", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "255168da-653e-4af0-baf8-a2d53b3c5116", "citation": "SARS-CoV-2-induced humoral immunity through B cell epitope analysis and neutralizing activity in COVID-19 infected individuals in Japan", "url": "https://www.biorxiv.org/content/10.1101/2020.07.22.212761v1.full.pdf", "doc_type": "WEB PAGE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "4f6daf48-df8f-4f6f-96c8-190bdce6b57a", "citation": "https://clinicaltrials.gov/ct2/show/NCT04494984", "url": "https://clinicaltrials.gov/ct2/show/NCT04494984", "doc_type": "CLINICAL_TRIALS.GOV", "public_domain": true, "tags": [ "NOMEN", "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "a8d753d8-f60e-4614-9649-65ccc6a18353", "citation": "COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020)", "url": "https://sorrentotherapeutics.com/research/covid-19/covi-amg/", "doc_type": "MANUFACTURER PRODUCT DESCRIPTION", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "e6f885ef-c296-4895-b380-58ffee1051a8", "citation": "Adagio Therapeutics COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses that Pose Human Threat", "url": "https://pipelinereview.com/index.php/2020111976600/Antibodies/Adagio-Therapeutics-COVID-19-Antibody-Demonstrates-Best-in-Class-Breadth-and-Potency-Against-a-Range-of-Coronaviruses-that-Pose-Human-Threat.html", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "379c8b9f-c192-4e8d-b201-801c863ac779", "citation": "Logunov, Denis Y., et al. \"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.\" The Lancet 396.10255 (2020): 887-897.", "url": "https://www.sciencedirect.com/science/article/pii/S0140673620318663?via%3Dihub", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "1460efb8-e8a2-4b9d-b34f-225e575ce26f", "citation": " List P124", "url": "https://www.who.int/medicines/publications/druginformation/issues/124_List_INN_Proposed_List.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3c44f2c2-268a-4f09-b0c1-9f2aca8208ff", "citation": "Chagla, Zain. \"The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19≥ 7 days after the 2nd dose.\" Annals of Internal Medicine (2021).", "url": "https://www.acpjournals.org/doi/full/10.7326/ACPJ202102160-015", "doc_type": "JA", "public_domain": true }, { "uuid": "fb3e03bd-017a-40ae-9c55-40056da5af33", "citation": "Polack, Fernando P., et al. \"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.\" New England Journal of Medicine 383.27 (2020): 2603-2615.", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2034577", "doc_type": "JA", "public_domain": true }, { "uuid": "179cad9d-4c69-44b3-9b9a-e3197c7164e9", "citation": "Logunov, Denis Y., et al. \"Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia.\" The Lancet 396.10255 (2020): 887-897.", "url": "https://www.sciencedirect.com/science/article/pii/S0140673620318663?via%3Dihub", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "748a8e4f-6f36-42fb-a2b3-9873e3b08063", "citation": "https://www.astrazeneca.com/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html", "url": "https://www.astrazeneca.com/media-centre/press-releases/2020/development-of-covid-19-vaccine-azd1222-expands-into-us-phase-iii-clinical-trial-across-all-adult-age-groups.html", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "2bc33d89-8dc6-429a-af1e-08e8b59405c1", "citation": "P124", "url": "https://www.who.int/medicines/publications/druginformation/innlists/PL124-COVID.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "65b57406-e7aa-4b38-82ee-d06246ebc3e3", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "44405223-bea9-48ce-8acc-8cda6ef98247", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "106c1271-4d9e-41e3-97b7-dd4e3712ac5f", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "185b8f94-2f0c-48ca-96f1-c7048967a2a8", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "534c4c3b-590f-47e3-8091-a6a8966b5b08", "citation": "P124", "url": "https://www.who.int/medicines/publications/druginformation/innlists/PL124-COVID.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "b1c42e05-ac07-4e7b-b79b-48045ce257d0", "citation": "Ella, Raches, et al. \"Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report.\" medRxiv (2020).", "url": "https://www.medrxiv.org/content/10.1101/2020.12.21.20248643v1.full.pdf", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "5f91cef5-0781-44a3-9497-95b81a257129", "citation": "https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-covid-19-human-immune-globulin-product", "url": "https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-covid-19-human-immune-globulin-product", "doc_type": "WEB PAGE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "b13c9582-b946-4f50-80be-ef8af07bb658", "citation": "Zhu, Feng-Cai, et al. \"Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.\" The Lancet 396.10249 (2020): 479-488.", "url": "https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931605-6", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "4855e6ff-66b2-4c62-95a6-6a1eea0d2cd1", "citation": "https://www.genengnews.com/covid-19-candidates/covid-19-keeping-an-eye-on/sinovac-biotech/", "url": "https://www.genengnews.com/covid-19-candidates/covid-19-keeping-an-eye-on/sinovac-biotech/", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "06bb5806-c139-481b-a4ed-8fab74620b39", "citation": "P125", "url": "https://www.who.int/publications/m/item/inn-pl-125", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "f28a5c92-2094-4f43-a821-a1e9873e6d37", "citation": "P124", "url": "https://www.who.int/medicines/publications/druginformation/innlists/PL124-COVID.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "e49c3a39-78b0-4bc8-9fec-016e80f6ea9e", "citation": "Shuntai Zhou, Collin S Hill, Sanjay Sarkar, Longping V Tse, Blaide M D Woodburn, Raymond F Schinazi, Timothy P Sheahan, Ralph S Baric, Mark T Heise, Ronald Swanstrom, β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells, The Journal of Infectious Diseases, Volume 224, Issue 3, 1 August 2021, Pages 415–419, https://doi.org/10.1093/infdis/jiab247", "url": "https://academic.oup.com/jid/article/224/3/415/6272009", "doc_type": "JA", "public_domain": true }, { "uuid": "1d53fb8b-cafc-43c0-86d9-c6c423597038", "citation": "stn", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "5e83522a-c32d-44fb-9f75-e25176ac476a", "citation": "stn", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "1ca92f5e-92c1-456e-adba-8a8956c372fb", "citation": "https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C152208", "url": "https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C152208", "doc_type": "NCI THESAURUS", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "680418f0-108e-40dc-a3e7-1d116c63ab40", "citation": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11870", "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11870", "doc_type": "IUPHAR", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "49f99fa0-85b9-4e77-8715-a1bbb379654e", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "6c8b49ac-0c22-435e-b3cd-afd4a7deef65", "citation": "https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharma-announces-preclinical-data-highlighting", "url": "https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharma-announces-preclinical-data-highlighting", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "78b2b7ac-0135-4110-88e2-d43a93e8bfcd", "citation": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11871", "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11871", "doc_type": "IUPHAR", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "9c6ddbe6-1990-44d8-8935-794f959f02b8", "citation": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11870", "url": "https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11870", "doc_type": "IUPHAR", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "126028e1-b9b7-476f-a6e4-ded1da35db7b", "citation": "Mlcochova, P., Kemp, S.A., Dhar, M.S. et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. Nature 599, 114–119 (2021). https://doi.org/10.1038/s41586-021-03944-y", "url": "https://www.nature.com/articles/s41586-021-03944-y", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "32518bf5-739a-404b-ba91-9f9afff79213", "citation": "Biochemistry 2021, 60, 39, 2925–2931 Publication Date:September 10, 2021 https://doi.org/10.1021/acs.biochem.1c00414", "url": "https://pubs.acs.org/doi/10.1021/acs.biochem.1c00414", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c9b6b858-06a0-458a-bb7a-1623ccafa172", "citation": "Shrimp, Jonathan H., et al. \"An enzymatic TMPRSS2 assay for assessment of clinical candidates and discovery of inhibitors as potential treatment of COVID-19.\" ACS pharmacology & translational science 3.5 (2020): 997-1007.", "url": "https://pubs.acs.org/doi/epdf/10.1021/acsptsci.0c00106", "doc_type": "JA", "public_domain": true }, { "uuid": "88427d1c-0a77-4c08-8caf-56819561f295", "citation": "NCT05367843", "url": "https://classic.clinicaltrials.gov/ct2/show/NCT05367843", "doc_type": "CLINICAL_TRIALS.GOV", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "0ccf9dd0-4811-4c7c-8faa-94db6e43e24e", "citation": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e0651c7a-2fe2-459d-a766-0d59e919f058", "doc_type": "DAILYMED", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "7c876b3f-408e-4317-96f9-5c6145a2b25c", "citation": "https://www.pharmaceutical-technology.com/news/german-researchers-covid-19-drug/", "doc_type": "WEB PAGE", "public_domain": true }, { "uuid": "256da0c0-0682-40cf-8e8c-1bf60acb1fb3", "citation": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "url": "https://www.cell.com/cell/fulltext/S0092-8674(20)30229-4?rss=yes#%20", "doc_type": "JA", "public_domain": true }, { "uuid": "1374dd52-5660-424c-b17a-3d9e713193ac", "citation": "Proposed INN: List 129 – COVID-19", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/inn-pl-129-covid.pdf?sfvrsn=4ce4122c_3&download=true", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "7eab14f3-6e5d-4aa7-9b6a-3a99172f3fe8", "citation": "INN P129", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf?sfvrsn=678fceea_3&download=true", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "08cd1275-63dc-48c4-9886-10d0349c098d", "citation": "Eng, Heather, et al. \"Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.\" Drug Metabolism and Disposition 50.5 (2022): 576-590.", "url": "https://dmd.aspetjournals.org/content/50/5/576?casa_token=Hbro9LzZP1UAAAAA:AcQwZ23y6zmAVd31ZaZhjhd2o7XBd_Cu1S2buTUigrhu_VZzdvJjKw9OabfKSMvnqaqYgMGQeN_7", "doc_type": "JA", "public_domain": true }, { "uuid": "679c5e3b-0866-448a-bb49-d049b679e685", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "1df5ccf2-3bbf-40d1-b026-1a01874e9b94", "citation": "Eng, Heather, et al. \"Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.\" Drug Metabolism and Disposition 50.5 (2022): 576-590.", "url": "https://dmd.aspetjournals.org/content/50/5/576?casa_token=Hbro9LzZP1UAAAAA:AcQwZ23y6zmAVd31ZaZhjhd2o7XBd_Cu1S2buTUigrhu_VZzdvJjKw9OabfKSMvnqaqYgMGQeN_7", "doc_type": "JA", "public_domain": true }, { "uuid": "cc5295c3-efa8-4364-b665-af8db6947431", "citation": "https://www.hilarispublisher.com/open-access/ezrin-peptide-therapy-a-potential-treatment-for-covid.pdf", "url": "https://www.hilarispublisher.com/open-access/ezrin-peptide-therapy-a-potential-treatment-for-covid.pdf", "doc_type": "WEBSITE", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "3a83d6af-24e5-4ef9-9095-060b4c566099", "citation": "INN PL127", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "2978b9eb-57f8-4401-99bb-3dba044fb8c6", "citation": "INN PL127", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8462f898-6d48-4986-97d6-76e9add6df6e", "citation": "INN PL127", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c2fcbd6f-0cbe-4233-a396-cf39f2896dc1", "citation": "INN PL127", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ea0681c2-da4c-45d0-bb18-24c67b6db3f6", "citation": "INN PL127", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl127.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "0691cb96-c693-489a-a43e-40d2e5cd915e", "citation": "https://www.mdpi.com/2227-9059/9/9/1254", "url": "https://www.mdpi.com/2227-9059/9/9/1254", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "bc22e3b9-0721-46f9-a39a-ddaf8eaf7911", "citation": "stn", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "d3488c4e-94ff-42d1-b88c-9a1337037a51", "citation": "https://www.pnas.org/doi/10.1073/pnas.2023051118", "url": "https://www.pnas.org/doi/10.1073/pnas.2023051118", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "f4297f7c-3f7d-4b39-a311-e575eaaaca52", "citation": "Jiang, Xiangrui, et al. \"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir.\" Nature Communications 14.1 (2023): 6463.", "url": "https://www.nature.com/articles/s41467-023-42102-y", "doc_type": "JA", "public_domain": true }, { "uuid": "3456bc04-7ee6-4ad3-9d40-0f50277d9792", "citation": "Xie, Yuanchao, et al. \"Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2.\" Cell research 31.11 (2021): 1212-1214.", "url": "https://www.nature.com/articles/s41422-021-00570-1", "doc_type": "JA", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "2001f23c-2078-4d24-a1e9-f2e1eb14dd01", "citation": "Qian, Hong-jie, et al. \"Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects.\" Acta Pharmacologica Sinica 43.12 (2022): 3130-3138.", "url": "https://www.nature.com/articles/s41401-022-00895-6", "doc_type": "JA", "public_domain": true }, { "uuid": "614aac2c-6ebf-47e0-9e2c-09ecd30519d8", "citation": "CA3214455 (Scifinder ref)", "doc_type": "PATENT", "public_domain": true }, { "uuid": "7c4e30e9-3f28-486c-9932-d9d1d6d55936", "citation": "MHRA", "doc_type": "MHRSA", "public_domain": true }, { "uuid": "ea53a4ba-ac38-4450-9fdd-ed331a9e7118", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "b96506c7-98cb-41ea-b923-48b88816bd8c", "citation": "INN P129", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf?sfvrsn=678fceea_3&download=true", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "0c30b72f-a1f3-42dc-b4bc-a68a2f74ecd8", "citation": "FDA_SRS", "doc_type": "SRS", "public_domain": true }, { "uuid": "00102b98-470c-42d2-b766-a0cd661d5080", "citation": "INN P129", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf?sfvrsn=678fceea_3&download=true", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "67b83ea9-b3a5-40ad-b20d-27d0c3734c2f", "citation": "Proposed INN: List 129 – COVID-19", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/inn-pl-129-covid.pdf?sfvrsn=4ce4122c_3&download=true", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "fbe3b2f1-811e-43c7-8589-824bb425245a", "citation": "Proposed INN: List 129 – COVID-19", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/inn-pl-129-covid.pdf?sfvrsn=4ce4122c_3&download=true", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "ba3dc0cb-6561-4218-a374-44c6a162ed08", "citation": "List 131", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "2a7cfef9-4181-4095-99ce-1d54a5289a94", "citation": "INN-131", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c0ef9b4c-4fb1-4a51-bf89-f1d43f7afd64", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "64c24cd4-c9da-4d71-a0d4-f57b73ac2d72", "citation": "INN LIST 130 ", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "d2f3a49c-1b1d-47e7-b55c-2a8003374e20", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c8a48031-06b7-47fb-b6c8-e88b1b238519", "citation": "Proposed INN: List 129 – COVID-19", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/inn-pl-129-covid.pdf?sfvrsn=4ce4122c_3&download=true", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "c857acb5-6a70-4a0d-8faa-b22e3388a3d6", "citation": "INN LIST 130 ", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "2e91007b-724d-4c86-ae11-64383e01f374", "citation": "INN LIST 130 ", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl130.pdf", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "78f97143-6ae0-47ff-85f2-64f5ef047972", "citation": "stn", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "8402e05f-61e0-48ca-a5b4-807d4433d114", "citation": "stn", "doc_type": "STN (SCIFINDER)", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "acc37f84-4962-4734-b42a-52b2d605897d", "citation": "INN P129", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl129.pdf?sfvrsn=678fceea_3&download=true", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "535509ee-7cf9-49fb-b78f-b1ac3ea86446", "citation": "STN", "doc_type": "STN (SCIFINDER)", "public_domain": true }, { "uuid": "7cdc583f-827e-4480-9c5d-cbd3be531e12", "citation": "List 132", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "eab52952-1fee-49a0-a284-b971652bd4e4", "citation": "Mednet", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "b8c58027-0bad-4121-9f56-ea59c4cfd7cb", "citation": "List 132", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "7c4114ea-4dc9-4d85-bc34-db069f881362", "citation": "List 132", "url": "https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl132.pdf", "doc_type": "INN", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] }, { "uuid": "1ead9006-39ec-4f59-a91a-b3388f565fa0", "citation": "Proposed INN: List 132", "doc_type": "INN_LIST", "public_domain": true, "tags": [ "PUBLIC_DOMAIN_RELEASE" ] } ], "definition_type": "PRIMARY", "definition_level": "COMPLETE", "uuid": "de824f40-fa1a-43f8-8168-fb46669a9941", "version": "288", "structurally_diverse": { "uuid": "c9a50923-fd67-7d4c-df5a-f5c8ac53d4e9", "infra_specific_name": "SARS-CoV-2", "infra_specific_type": "STRAIN", "organism_author": "NONE", "organism_family": "Coronaviridae", "organism_genus": "Betacoronavirus", "organism_species": "severe acute respiratory syndrome-related coronavirus", "part": [ "whole" ], "references": [ "d4383a4b-0dc2-fbf0-8bf0-99f242c265db", "3de32c20-281e-8ad1-c372-1bfa9622e2c0", "1812aef1-937f-4b3d-b930-76639adf4d0f" ], "source_material_class": "ORGANISM", "source_material_state": "LIVE", "source_material_type": "VIRUS" }, "modifications": { "uuid": "38288256-9af6-94fa-63bd-d4734990a5a4" }, "unii": "B6L4N5Z4GH" } ] }